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9ABSTRACT
Much of the present understanding of the
development of human cancer has arisen
through studies of rare, dominantly inherited
cancer syndromes. Investigations of cancer
susceptibility have revealed several genes
involved in the development of both
hereditary and sporadic cancer forms.
Furthermore, identification of these genes
has provided a means for diagnostic testing
of predisposed individuals and subsequent
cancer prevention in individuals at risk.
Although many cancer syndromes with
distinct features have been characterized,
novel disease forms no doubt exist. This
study describes a previously unrecognized
cancer syndrome with predisposition to
leiomyomas of the uterus and skin, uterine
leiomyosarcoma, and renal cancer
(hereditary leiomyomatosis and renal cell
cancer, HLRCC).
Hereditary renal cancer has
conventionally been divided into two well-
characterized syndromes. von Hippel-Lindau
disease (VHL), associated with clear cell
renal carcinoma and vascular tumors of the
retina and central nervous system, is caused
by a germline mutation in the VHL tumor
suppressor gene in 3p25. Hereditary
papillary renal cell carcinoma (HPRC),
which is associated with multiple bilateral
papillary renal carcinomas, is caused by
mutations in the MET oncogene in 7q21. In
addition, renal cancer is associated with
other hereditary tumor predisposition
conditions such as tuberous sclerosis (TS)
and Birt-Hogg-Dubé syndrome (BHD).
Uterine leiomyomas (fibroids,
myomas) are the most common tumors in
women, with a prevalence of over 25%.
They have a major impact on women's
health by causing morbidity and infertility
and being the leading cause of hysterectomy.
Despite the clinical relevance of these
lesions, little is known about their molecular
background. In rare cases, hereditary
predisposition to uterine leiomyomas can be
observed together with susceptibility to
cutaneous leiomyomas (multiple cutaneous
and uterine leiomyomatosis, MCL).
In this study, we identified a novel
tumor predisposition condition, HLRCC.
Multiple lines of evidence supported this
conclusion. First, the tumor spectrum in the
disease families, i.e. susceptibility to uterine
and/or cutaneous leiomyomas, uterine
leiomyosarcoma, and renal cancer, had not
been proposed before. Second, the renal cell
carcinoma phenotype was unique. The
tumors displayed exceptional papillary
histology that could also be used to identify
additional families. The third and most
conclusive evidence was localization of the
disease gene to 1q42-q43 by genome-wide
search. The linkage was confirmed by
detecting wild-type allele loss at this locus in
the majority of patients’ tumors, which also
suggested that the underlying genetic defect
would impair the function of a tumor
suppressor gene. Furthermore, we found that
a family originally diagnosed with MCL
displayed similar clinical, histopathological,
and molecular features as in HLRCC. These
findings, together with a subsequent and
independent study reporting linkage to the
same chromosomal region in MCL families,
demonstrated that MCL and HLRCC are a
single disease with a variable phenotype.
Through mutation screening of
known and predicted transcripts in the
susceptibility locus, we identified the
Maija Kiuru
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disease-predisposing gene, f umara t e
hydratase (fumarase, FH). FH encodes an
enzyme component of the mitochondrial
tricarboxylic acid (Krebs) cycle, thus
playing a key role in cellular energy
metabolism. Germline mutations in FH were
detected in 25 of 42 HLRCC and
leiomyomatosis families and included
protein-truncat ing mutat ions and
substitutions or deletions of highly
conserved amino acids. Both F H alleles
were inactivated in almost all patients’
tumors. Moreover, FH enzyme activity was
reduced in patients’ normal tissues and was
almost absent in their tumors. Thus, we
demonstrated that germline mutations in FH
underlie HLRCC and that FH is a putative
tumor suppressor gene.
To investigate the role of FH
mutations in sporadic tumorigenesis, we
performed mutation analyses on a series of
sporadic counterparts of tumor types
associated with HLRCC. Although
mutational inactivation of FH appeared to be
rare in the studied tumor series, biallelic
inactivation of FH was detected in a uterine
leiomyosarcoma, a cutaneous leiomyoma,
and a soft-tissue sarcoma. Whereas the two
former tumors originated from a germline
mutation, the sarcoma displayed two somatic
hits. These findings supported our previous
results on the robust biallelic inactivation
pattern of FH and demonstrated that FH
could be involved in the development of
nonhereditary tumors.
Identification of FH in cancer
predisposition provides insights into
development of leiomyomas, leiomyo-
sarcoma, and renal cell carcinoma. This
study is the first to show mutations in a gene
encoding a Krebs cycle enzyme in common
human tumors. Elucidation of the molecular
basis of HLRCC could facilitate diagnosis,
detection, and prevention of tumors in the
predisposed individuals. Moreover, the
findings of this study could shed light on the
molecular pathogenesis of the sporadic
disease form, thus being relevant for larger
populations, including women affected with
uterine leiomyomas.
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INTRODUCTION
Cancer is one of the leading causes of
morbidity and death in developed countries.
Up to every third individual develops cancer
and every fifth dies from it. Epidemiological
studies have shown that environmental and
lifestyle factors, such as smoking, diet,
certain viruses, radiation, and reproductive
and hormonal factors, increase cancer risk
(Peto, 2001). At the molecular level, various
exogenous and endogenous carcinogens
cause damage to the DNA. Accumulation of
genetic changes then leads to transformation
of normal cells into cancer cells (Nowell,
1976; Hanahan and Weinberg, 2000; Ponder,
2001). Thus, cancer is a disease of the
genome.
The great majority of malignancies
occur sporadically due to acquired
mutations. Although no apparent family
history can be detected in these cases, the
genotypic profile has nevertheless been
proposed to play a role in determining the
cancer risk (Ponder, 2001). A small subset of
cancers cluster in families. In these familial
cancer cases, inherited genetic defects
predispose to malignancy. Cancer
predisposition can vary from weak to strong
depending on the penetrance of the gene
(Ponder, 2001). Susceptibility to malignancy
is high in hereditary cancer syndromes,
which account for approximately 1% of
human cancers. These diseases are typically
characterized by tumor development at an
early age, bilateral disease, multiple primary
tumors, and association with other clinical
manifestations (Marsh and Zori, 2002).
To date, the genetic basis for over 20
hereditary cancer syndromes has been
elucidated (Kinzler and Vogelstein, 2002).
Studies on these diseases have provided
insights into the mechanisms of cancer
development. Furthermore, in clinical
practice, diagnostics and prevention of the
diseases have been improved through
genetic testing and regular screening for
tumors in individuals at risk.
Although many cancer syndromes
with distinct features have been
characterized, some previously unrecognized
disease forms are likely to exist. This study
describes clinical, histopathological, and
molecular features of a novel dominantly
inherited tumor predisposition syndrome
with susceptibility to uterine and cutaneous
leiomyomas and papillary renal cell
carcinoma (hereditary leiomyomatosis and
renal cell cancer, HLRCC). The findings of
this study increase the present knowledge of
inherited cancer susceptibility and of the
molecular background of some common
human tumor types, including leiomyomas,
the most prevalent tumors in women.
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REVIEW OF THE LITERATURE
1. CANCER AND GENES
Cancer is characterized by clonal expansion
of cells, which become malignant via a
series of genetic alterations (Fearon and
Vogelstein, 1990). Through accumulation of
genetic changes, the cells acquire properties
typical of the cancerous phenotype. Hanahan
and Weinberg (2000) have proposed six
groups of such features: self-sufficiency in
signals stimulating growth, insensitivity to
negative growth signals, evasion of
programmed cell death, capacity for
sustained proliferation, angiogenesis, and
tissue invasion and metastasis. A widely
documented example of the multistep
process of tumorigenesis is development of
colorectal carcinoma, which is distinguished
by well-defined histological stages and
referred to as the adenoma-carcinoma
sequence (Vogelstein et al., 1988; Fearon
and Vogelstein, 1990). Progression from
normal epithelium to carcinoma occurs
through adenomatous stages and is
characterized by accumulation of genetic
alterations (Figure 1). The changes include
either inactivation of tumor suppressor genes
or activation of oncogenes, giving cells a
growth advantage over the normal cell
population and thus leading to malignancy.
1.1 Oncogenes
Oncogenes are mutated forms of normal
cellular components, proto-oncogenes.
Mutations in proto-oncogenes enhance their
function, providing cells with a growth
advantage. Oncogenes were initially
discovered in viral genomes (e.g. v-src), as
they were able to transduce normal cellular
genes to become constitutively active, and
thus, induce tumorigenesis (Stehelin et al.,
1976; Bishop, 1981). The protein products
of proto-oncogenes are highly conserved in
evolution and are involved in normal cellular
signaling regulating cell growth and
differentiation. In human cancer, proto-
oncogenes are activated through genetic
alterations, such as gain-of-function
mutations, gene amplifications, and
chromosomal translocations (Bishop, 1991).
A single activating mutation in one of the
two alleles is sufficient to promote abnormal
growth. Thus, oncogenes are dominant at the
cellular level. To date, over 100 oncogenes
have been identified (Futreal et al., 2001).
Figure 1. A simplistic model of multiple steps in colorectal tumorigenesis (modified from Vogelstein et al.,
1988; Fearon and Vogelstein, 1990).
Normal
epithelium
APC SMAD2 p53
SMAD4
K-RAS
Prolferative
changes
Early
adenoma
Intermediate
adenoma
Late
adenoma
Carcinomain
situ
Invasive
carcinoma
Metastasis
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1.2 Tumor suppressor genes
Tumor suppressor genes are negative
regulators of cell growth (Marshall, 1991;
Weinberg, 1991). The first observations
supporting the existence of these genes came
from somatic cell studies. Tumor cell growth
was demonstrated to be suppressed by fusing
nonmalignant cells with cancer cells
(Ephrussi et al., 1969; Harris, 1988). Later,
the reversion to the tumorigenic phenotype
was shown to be associated with loss of
specific chromosomal material (Shimizu et
al., 1990; Trent et al., 1990).
The leading evidence for the
presence of tumor suppressor genes came
through studies on the childhood eye tumor
retinoblastoma. Knudson (1971) suggested
that two mutational events were required for
retinoblastoma development. In hereditary
cases, one mutation was inherited via the
germline of an individual and the second
mutation occurred at the somatic level. In
the nonhereditary forms of the disease, by
contrast, the two events were somatic, and
thus, less likely to occur. The two genetic
events in the Knudson’s model were
subsequently shown to represent biallelic
inactivation of a tumor suppressor gene. This
was demonstrated by cloning of the
retinoblastoma (RB) gene and detecting loss-
of-function mutations in both RB alleles in
retinoblastomas (Lee et al., 1987).
In addition to R B , the two-hit
inactivation pattern has been demonstrated
in other tumor suppressor genes as well.
Whereas the first hit is either an inherited or
a somatic mutation in a given tumor
suppressor gene, the second hit is often a
gross chromosomal mechanism, resulting in
hemi- or homozygosity of the chromosomal
region containing the respective gene, i.e.
loss of heterozygosity (LOH). Such
chromosomal events include deletion, gene
conversion, nondisjunctional chromosome
loss, and mitotic recombination. LOH can be
detected by comparing the genotypes of the
tumor and the corresponding normal tissue
at a given polymorphic marker (Devilee et
al., 2001). In addition to genetic changes,
epigenetic mechanisms, such as
transcriptional silencing through promoter
hypermethylation, can lead to functional
inactivation of tumor suppressor gene alleles
(Jones and Baylin, 2002).
1.1.1 Gatekeepers, caretakers, landscapers
Approximately 30 tumor suppressor genes
have been identified thus far (Futreal et al.,
2001). Due to the growing number of these
genes and knowledge about the functional
roles of the gene products, they have been
further defined and classified. Tumor
suppressors have been suggested to include
‘genes that sustain loss-of-function mutation
in the development of cancer’ (Haber and
Harlow, 1997). This broad definition
includes all such genes regardless of their
presumed function and thus takes into
account the obscurity of the mechanisms by
which inactivation of a tumor suppressor
gene actually leads to tumor development.
Genes harboring loss-of-function
mutations can be classified as ‘gatekeepers’
or ‘caretakers’ depending on their putative
role in the cellular processes (Kinzler and
Vogelstein, 1997). Gatekeepers are thought
to directly regulate tumor growth by
inhibiting proliferation or promoting cell
death. In the multistep process of cancer
development, each cell type presumably has
certain gatekeepers whose inactivation is
rate-limiting for tumor initiation (Kinzler
and Vogelstein, 1997). According to
Knudson’s model, cells undergo neoplastic
transformation when both copies of a given
gene are inactivated in the target tissue. For
example, RB, VHL, NF1, and APC have
been proposed to be gatekeepers of tumor
growth in the retina, kidney, Schwann cells,
Maija Kiuru
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and colon, respectively (Kinzler and
Vogelstein, 1997).
In contrast to gatekeepers, caretakers
inhibit tumor growth indirectly by
maintaining genomic integrity (Kinzler and
Vogelstein, 1997). Mutations in caretaker
genes increase genetic instability, leading to
an elevated mutation rate in all genes,
including tumor suppressor genes and
oncogenes. Thus, cancer development is
accelerated. Caretakers include genes
involved in DNA repair and replication, such
as mismatch repair genes and BRCA1 and
BRCA2 genes mutated in the well-known
hereditary cancer syndromes hereditary non-
polyposis colorectal cancer (HNPCC) and
familial breast and ovarian cancer,
respectively (see section 1.3 and Table 1).
A third category of tumor
suppressors, ‘landscapers’, has also been
proposed (Kinzler and Vogelstein, 1998).
Defects in landscapers are speculated to
contribute to neoplastic transformation by
generating an abnormal stromal
environment, and thus, abnormal
intercellular signaling. The landscaper effect
has been suggested to occur in juvenile
polyposis syndrome (JPS) (Kinzler and
Vogelstein, 1998). According to the theory,
increased colon cancer risk in JPS results
from the effects of abundant stroma on
epithelial cells in hamartomatous colonic
polyps.
1.3 Genes for hereditary cancer
Studies on rare hereditary cancer syndromes
have revealed several genes predisposing to
cancer (Table 1). Most hereditary cancer
syndromes are caused by germline mutations
in tumor suppressor genes. In rare cases,
however, inherited mutations in proto-
oncogenes have been shown to cause
susceptibility to cancer. These genes include
MET, RET, and CDK4, causing hereditary
papillary renal cell carcinoma (HPRC),
multiple endocrine neoplasia type 2, and
familial melanoma, respectively. Although
most hereditary cancer syndromes are
dominantly inherited, a few autosomal
recessive diseases exist, such as ataxia-
teleangiectasia, Bloom’s syndrome, Fanconi
anemia, and xeroderma pigmentosum.
Mutations in some of the cancer-
susceptibility genes have been shown to be
key features not only in hereditary but also
in sporadic cancers. Examples of such genes
are APC  and VHL , which cause familial
adenomatous polyposis (FAP) and the
hereditary renal cancer syndrome von
Hippel-Lindau disease (VHL), respectively.
Mutations in APC are present in 85-90% of
colorectal cancers (Kinzler and Vogelstein,
1996). Loss of VHL  can be detected in
almost all clear cell renal carcinomas. Over
half of them display biallelic inactivation of
VHL through loss of one allele and somatic
mutation or promoter hypermethylation of
the other allele (Gnarra et al., 1994; Herman
et al., 1994).
Studies on cancer-susceptibility
genes have provided insights into
tumorigenic mechanisms. In addition to the
biallelic inactivation of a tumor suppressor
gene, other phenomenons, including
epigenetic silencing (Jones and Baylin,
2002) and haploinsufficiency (Quon and
Berns, 2001), have been shown to contribute
to tumorigenesis. Genes such as p53 ,
p27Kip1, and LKB1 have been suggested to
be haploinsufficient for tumor suppression,
i.e. losing only one allele is sufficient for
t u m o r  i n i t i a t i o n
Table 1. Some genes predisposing to hereditary cancer syndromes (Modified from Marsh and Zori, 2002).
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Syndrome Gene and location Proposed
category of
the gene
Tumor spectrum Protein function
Ataxia-
teleangiectasia
ATM (11q22-q23) Caretaker Breast cancer,
leukemia, lymphoma
Protein kinase
Maintenance of genomic integrity
Bannayan-
Riley-
Ruvalcaba
syndrome
PTEN (10q23.3) Gatekeeper Intestinal
hamartomas, breast
and thyroid cancers
Phosphatase inhibiting PI3K-Akt
pathway
Regulation of cell cycle, apoptosis,
angiogenesis
Bloom’s
syndrome
BLM (15q26.1) Caretaker Leukemia,
lymphoma, multiple
carcinomas
DNA helicase
Maintenance of genomic integrity
Carney
complex
PRKR1A (17q22-
q24)
TSG Cardiac myxomas,
other myxomas,
endocrine tumors,
melanotic
schwannomas
Protein kinase A regulatory subunit
Role in the cAMP pathway
Cowden
syndrome
PTEN (10q23.3) Gatekeeper Intestinal
hamartomas, breast
and thyroid cancers,
skin tumors
Phosphatase inhibiting PI3K-Akt
pathway
Regulation of cell cycle, apoptosis,
angiogenesis
Familial
adenomatous
polyposis
APC (5q21) Gatekeeper Adenomatous polyps
of the colorectum,
colorectal, small
intestinal, and gastric
cancers, osteomas,
desmoid tumors,
medulloblastoma
Sequestering ß-catenin in cytoplasm
Regulation of cell proliferation,
migration, adhesion, chromosomal
stability
Familial breast
and ovarian
cancer
BRCA1 (17q21),
BRCA2 (13q12.3)
Caretaker Breast and ovarian
cancers, BRCA2 also
in prostate and male
breast cancers
Maintenance of genomic integrity
(involved in DNA repair)
Familial gastric
cancer
E-cadherin (16q22) Gatekeeper Gastric cancer Interaction with ß-catenin and
regulation of cell adhesion
Familial
melanoma
CDKN2 (p14, p16,
p19ARF) (9p21)
CDK4 (12q14)
Gatekeeper
Proto-
oncogene
Melanoma,
pancreatic, bladder,
and esophageal
cancers, leukemia
Melanoma
Inhibition of cyclin-dependent
kinases and blocking of cell cycle
(p14, p16)
Regulation of p53 through MDM2
(p19ARF)
Promotion of cell cycle progression
Familial
paraganglioma
and
pheochromo-
cytoma
SDHD (11q23),
SDHC (1q21),
SDHB (1p36.1-p35)
TSG Paragangliomas,
pheochromo-cytomas
Mitochondrial complex II subunits:
iron sulfur protein (SDHB), integral
membrane proteins (SDHC, SDHD)
Involved in the Krebs cycle and the
electron transport chain
Fanconi
anemia
FANCA (16q24.3),
FANCC (9q22.3),
FANCD2 (3p25.3),
FANCE (6p22-p21),
FANCF (11p15),
FANCG (9p13),
BRCA2 (13q12)
Caretaker Leukemia, squamous
cell carcinoma
Maintenance of genomic integrity
Hereditary
nonpolyposis
colorectal
cancer
MSH2 (2p16),
MLH1 (3p21),
PMS1 (2q32),
PMS2 (7p22),
MHS3 (5q11-q12),
MSH6 (2p16)
Caretaker Colorectal,
endometrial,
stomach, ovarian,
hepatobiliary, and
urinary tract cancers,
glioblastoma
DNA mismatch repair
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Hereditary
papillary renal
cell carcinoma
MET (7q31) Proto-
oncogene
Papillary renal cell
carcinoma
Receptor tyrosine kinase
Juvenile
polyposis
SMAD4 (18q21),
BMPR1A (10q22)
Gatekeeper,
putative
landscaper
(SMAD4)
Intestinal juvenile
polyps, cancer risk
elevated
Signal transductor in TGFß pathway
(SMAD4)
Member of TGFß-receptor
superfamily, upstream from the
SMAD pathway (BMPR1A)
Li-Fraumeni p53 (17p13)
CHK2 (22q12.1)
Gatekeeper Sarcomas, breast
cancer, brain tumors,
leukemia,
adrenocortical tumors
Transcription factor, regulation of
apoptosis, cell cycle, angiogenesis
(p53)
Checkpoint kinase, involved in DNA
damage response (CHK2)
Multiple
endocrine
neoplasia type
1
MEN1 (11q13) Unknown Pancreatic islet cell
tumors, pituitary
adenomas,
parathyroid
hyperplasia,
Interaction with the AP-1
transcription factor JunD and
repression of JunD-activated
transcription
Multiple
endocrine
neoplasia type
2
RET (10q11) Proto-
oncogene
Medullary thyroid
carcinoma,
pheochromocytoma,
parathyroid
hyperplasia
Receptor tyrosine kinase
Neurofib-
romatosis type
1 and type 2
NF1 (17q11), NF2
(22q12)
Gatekeeper Neurofibromas,
neurofibrosarcomas,
glioma, astrocytoma,
meningeomas,
schwannomas
Regulation of Ras signaling
Neurofib-
romatosis type
2
NF2 (22q12) Gatekeeper Neurofibromas,
neurofibrosarcomas,
glioma, astrocytoma,
meningeomas,
schwannomas
Maintenance of cytoskeleton,
suppressor of cell adhesion, motility,
and spreading
Nevoid basal
cell carcinoma
syndrome
PTCH (9q22.3) Gatekeeper Basal cell skin
carcinoma,
medulloblastoma
Transmembrane receptor in sonic
hedgehog pathway
Peutz-Jeghers
syndrome
LKB1 (19p13.3) Gatekeeper Intestinal
hamartomas, small
intestinal, gastric,
colorectal, pancreatic,
breast, and ovarian
cancers, testicular
tumors
Serine/threonine kinase
Regulation of cell cycle
Retinoblastoma RB1 (13q14) Gatekeeper Retinoblastoma,
osteosarcoma
Cell cycle control
Tuberous
sclerosis
TSC1 (9q34),
TSC2 (16p13)
Gatekeeper Hamartomas, renal
cell carcinoma,
angiomyolipoma,
astrocytoma
Regulation of cell proliferation,
growth, adhesion
Werner
syndrome
RECQL2 (8p12-
p11)
Caretaker Sarcomas,
meningeomas,
thyroid cancer,
melanoma
DNA helicase and exonuclease
Maintenance of genomic integrity
Wilms tumor WT1 (11p13) Gatekeeper Nephroblastoma
(embryonal childhood
tumor in kidney)
Zinc finger transcription factor
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von Hippel-
Lindau
syndrome
VHL (3p25) Gatekeeper Clear cell renal
carcinoma,
pheochromocytomas,
retinal angiomas,
hemangioblastomas
Component of ubiquitin-ligase
complex
Degradation of HIF-1_ transcription
factor
Involved in regulation of cell cycle,
energy metabolism, adhesion,
angiogenesis
Xeroderma
pigmentosum
XPA (9q22),
XPB (2q21),
XPC (3p25),
XPD (19q13),
XPE (11p12),
XPF (16p13)
XPG (13q32)
Caretaker Melanoma, basal cell
carcinoma
DNA excision repair
(Fero et al., 1998; Venkatachalam et al.,
1998; Rossi et al., 2002). However, the
biallelic inactivation of a tumor suppressor
gene has been proposed to contribute to
tumor progression and more severe tumor
susceptibility (Quon and Berns, 2001; Rossi
et  al . ,  2002).  The degree of
haploinsufficiency may vary among tumor
suppressor genes, ranging from no apparent
effect to weak or strong effects (Cook and
McCaw, 2000; Quon and Berns, 2001).
1.4 The Human Genome Project
The Human Genome Project was launched
over a decade ago to create publicly
available high-quality sequences of genomes
of human and key model organisms (Human
Genome Project Information Website,
2002). Within the last decade, the program
has rapidly progressed from generation of
genetic (Weissenbach et al., 1992) and
physical (McPherson et al., 2001) maps to
production of a draft sequence of the human
genome (Lander et al., 2001). Based on
preliminary analysis of the draft genome
sequence, the human genome is estimated to
contain 30 000-40 000 protein-coding genes,
which is only about twice as many as in a
worm or a fly (Lander et al., 2001). In
addition to the public effort, a private
company, Celera Genomics, has reported a
nearly complete sequence of the human
genome (Venter et al., 2001). The final
phase of the Human Genome Project aims to
produce a complete sequence of the human
genome by 2003.
After the Human Genome Project
achieves its primary goal of the production
of a publicly available sequence of the
human genome, several other objectives
remain to be met. One of the most important
of these is to further analyze and interpret
the raw sequence data to understand its
biological significance (Stein, 2001). The
process of genome annotation includes
identifying genes and their regulatory
regions, completing the map of human
genome sequence variation, classifying and
characterizing proteins, and relating the
genome to biological processes. The rapidly
expanding human genome data pool also
requires concurrent examination and
evaluation of ethical, legal, and social
implications.
One of the key applications of human
genome research has been identification of
disease genes by positional cloning, i.e.
based on their chromosomal location.
Previously, this method included such
tedious and time-consuming steps as
generation of genetic markers, obtaining
genomic sequences by chromosomal
walking, and direct sequencing. Through
progression of the Human Genome Project,
the process has evolved into identification of
candidate genes in silico and subsequent
mutation screening of these sequences, thus
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facilitating the search for disease-
predisposing genes.
2. CARCINOMA OF THE KIDNEY
Cancer of the kidney accounts for
approximately 2% of cancer cases
worldwide (McLaughlin and Lipworth,
2000). Although it is less frequent than other
urologic cancers, namely prostate and
bladder carcinomas, it is the most malignant
one, causing death in over 35% of affected
individuals (Finnish Cancer Registry, 1999;
Van Poppel et al., 2000). Renal cancer
incidence has been increasing over the past
decades in North America and Northern
Europe (McLaughlin and Lipworth, 2000),
including Finland (Finnish Cancer Registry,
1999) (see Table 2 for cancer incidence in
Finland). Renal cell carcinoma most
commonly occurs between the ages of 50
and 70 years, and males are affected twice as
often as females. Smoking, obesity, and
occupational exposures are associated with
increased risk of renal cancer (McLaughlin
and Lipworth, 2000). Hereditary
predisposition is estimated to account for up
to 4% of all cases (Linehan et al., 1995).
2.1 Histopathological and molecular
features of renal neoplasms
Renal neoplasms consist of distinguishable
entities with characteristic morphological
and molecular features (Kovacs et al., 1997;
Störkel et al., 1997; Reuter and Presti, 2000)
(Table 3). The most common tumors of the
kidney are benign papillary adenomas,
which are discovered in up to 20% of
autopsies in adults (Van Poppel et al., 2000).
Almost all of the malignant neoplasms are
renal cell carcinomas originating from the
epithelium of proximal renal tubules and
collecting tubules. These include clear cell
(conventional), papillary, and chromophobe
renal cell carcinoma, and collecting duct
carcinoma. Wilm’s tumor, a pediatric cancer
of the kidney, is composed of blastemal,
stromal, and epithelial components, and is
usually excluded from classifications of
renal tumors (Linehan et al., 2002).
Traditionally, staging and grading of
tumors have been used to evaluate cancer
prognosis. The staging scheme for renal
tumors is based on the tumor-node-
metastasis (TNM) classification, and the
most widely used grading system is that
proposed by Fuhrman et al. (1982). The
Fuhrman classification divides tumors into
four grades based on nuclear size, nuclear
membrane irregularity, and nucleolar
prominence. The prognostic value of the
grading and staging systems varies between
different histological subtypes (Medeiros et
al., 1997; Reuter and Presti, 2000). Thus,
subgrouping of tumors is necessary. This has
been accomplished not only by evaluating
tumor histology but also by cytogenetic and
molecular profiling.
Clear cell carcinoma is the prevailing
histologic subtype of renal carcinomas,
comprising 70-75% of these tumors (Kovacs
et al., 1997; Störkel et al., 1997).
Histologically, clear cell carcinomas exhibit
either an exclusively solid or acinar growth
pattern, or a mixture of cystic,
pseudopapillary, and tubular structures.
Tumors are usually highly vascularized
(Reuter and Presti, 2000). Tumor cells are
cuboidal or polygonal in shape and have
predominantly clear cytoplasm. Cells with
eosinophilic or granular cytoplasm can also
be observed and are often associated
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Table 2. Prevalent cancer types in Finland (Finnish Cancer Registry, 1999).
Males N (%) Females N (%)
Prostate 3112 (29.2) Breast 3578 (31.7)
Lung, trachea 1473 (13.8) Colon 738 (6.5)
Colon 598 (5.6) Corpus uteri 695 (6.2)
Bladder, ureter, urethra 593 (5.6) Ovary 522 (4.6)
Stomach 445 (4.2) Lung, trachea 498 (4.4)
Rectum, rectosigmoid 440 (4.1) Skin, nonmelanoma 453 (4.0)
Kidney 417 (3.9) Nervous system 442 (3.9)
Skin, nonmelanoma 357 (3.4) Rectum, rectosigmoid 425 (3.8)
Nervous system 330 (3.1) Stomach 380 (3.4)
Melanoma of the skin 323 (3.0) Pancreas 342 (3.0)
Pancreas 315 (3.0) Non-Hodgkin’s lymphomas 333 (3.0)
Non-Hodgkin’s lymphomas 300 (2.8) Melanoma of the skin 317 (2.8)
Leukemia 216 (2.0) Kidney 299 (2.6)
Total 10643 (100.0) Total 11286 (100.0)
with higher nuclear grade.
Genetically, clear cell carcinomas are
characterized by losses of 3p (Kovacs, 1993)
and defects in VHL at 3p25 (Table 3), the
gene whose germline mutations cause the
most common hereditary renal cancer
syndrome, von Hippel-Lindau disease (see
section 2.2.1). In a study on V H L
involvement in sporadic renal cell
carcinomas, loss of one VHL  allele was
observed in as many as 98% of clear cell
carcinomas and mutational inactivation of
the other VHL allele in 57% of cases (Gnarra
et al., 1994). Promoter hypermethylation of
VHL was later detected in 4 of the 7 tumors
that had not displayed mutations in the
earlier study (Herman et al., 1994).
Inactivation of VHL has been shown to be
specifically associated with clear cell
carcinoma (Foster et al., 1994; Kenck et al.,
1996).
Papillary renal cell carcinoma
accounts for about 10-15% of renal
carcinomas (Kovacs et al., 1997). The
growth pattern of these lesions is
characterized by papillary fronds containing
a fibrovascular core and lined by neoplastic
epithelial cells. In addition, tumors usually
have small areas with tubular, tubulo-
papillary, and solid structures. Papillary
renal cell carcinomas can be further divided
into type 1 and type 2 tumors, as proposed
by Delahunt and Eble (1997). Type 1 and
type 2 histologies correspond to previous
divisions of tumors into basofilic and
eosinophilic subgroups, respectively
(Thoenes et al., 1986; Zambrano et al.,
1999). Type 1 tumors consist of small cells
with pale cytoplasm and small nuclei with
inconspicuous nucleoli and frequent
glomeruloid papillae with edema, foamy
macrophages, and psammoma bodies. In
contrast, type 2 tumor cells are larger, often
have abundant cytoplasm and a tendency
towards pseudostratification, and contain
large nuclei with prominent nucleoli.
Nuclear grade, growth kinetics, and survival
rates have been found to differ between type
1 and 2 tumors (Delahunt et al., 2001).
Approximately 80% of papillary
renal cell carcinomas have been observed to
contain chromosomal gains. Characteristic
changes include gains of chromosomes 7
and 17, and loss of chromosome Y in men
(Meloni et al., 1992; Kovacs, 1993). These
changes have also been detected in benign
papillary adenomas, suggesting the
possibility of an adenoma-carcinoma
sequence in development of papillary renal
tumors (Kovacs, 1993). Chromosome 7
harbors the MET  oncogene, which is the
predisposing gene for hereditary papillary
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renal cell carcinoma (HPRC) (see section
2.3.1). In addition to frequent gains of the
MET  locus in sporadic papillary tumors,
mutations in MET have been observed in
approximately 10% of these lesions
(Schmidt et al., 1997, 1999) (Table 3). In
addition, other chromosomal abnormalities,
such as somatic trans-location involving
chromosomes 1 and X, have been detected
in some papillary tumors (de Jong et al.,
1986; Tomlinson et al., 1991; Ohjimi et al.,
1993; Sidhar et al., 1996). In recent studies,
some genetic differences between type 1 and
2 papillary renal cell carcinomas have been
reported: gains of 7p and 17p and allelic
imbalance on 17q were more frequent in
type 1 than type 2 tumors, whereas allelic
imbalance on 9p was present only in type 2
tumors (Jiang et al. 1998; Sanders et al.,
2002).
Chromophobe renal cell carcinomas
account for 6-11% of renal carcinomas
(Reuter and Presti, 2000). Typically, tumors
display a solid or mixed growth pattern and
cells with either pale reticular or
eosinophilic granular cytoplasm (Kovacs et
al., 1997). The former group may be difficult
to distinguish from clear cell carcinoma and
the latter from oncocytoma. Oncocytomas
are benign tumors that are approximately as
common as chromophobe renal cell
carcinomas. They are well-circumscribed
lesions that contain nests and tubules of
epithelial cells. Cells are round or polygonal
and have abundant eosinophilic cytoplasm,
round nuclei with uniform contours and
prominent nucleoli, and high content of
mitochondria (Erlandson et al., 1997; Reuter
and Presti, 2000).
Due to different clinical behavior of
chromophobe carcinoma and onco-cytoma,
their diagnostic separation is important. The
most typical features of chromophobe
tumors, diffuse staining with Hale’s
colloidal iron and numerous cytoplasmic
microvesicles (Thoenes et al., 1985, 1988)
could help in differential diagnosis
(Skinnider and Jones, 1999). In addition to
histological features, specific genetic
changes have been used for characterization
although they partly overlap. Chromophobe
tumors harbor losses in chromosomes 1, 2,
6, 10, 13, 17, and 21 (Bugert and Kovacs,
1996) (Table 3). Loss of chromosome 1 is
also detected in oncocytomas, which are
usually heterogenous tumors with various
chromosomal alterations (Kovacs et al.,
1989; van den Berg et al., 1995; Herbers et
al., 1998) (Table 3). In addition,
oncocytomas have been shown to contain an
increased amount of mitochondrial DNA,
reflecting increased mitochondrial
Table 3. Classification of renal epithelial neoplasms (modified from Zambrano et al., 1999 and Reuter and
Presti, 2000).
Tumor type Genetic abnormalities Other genetic abnormalities
Malignant tumors
Clear cell (conventional) RCC - 3p, VHL mutations + 5q, - 8p, - 9p, - 14q
Papillary RCC + 7, + 17, - Y, MET mutations + 12, + 16, + 20, - 9p, - 11q, - 14q,
- 17p, - 21q
Chromophobe RCC - 1, - Y, - 2, - 6, - 10, - 13, - 17, - 21
Collecting duct carcinoma - 1, - 6, - 14, - 15, - 22 - 8, - 13
RCC, unclassified variable changes
Benign tumors
Papillary-tubular adenoma + 7, + 17, - Y
Oncocytoma no specific changes, - 1, - Y
Metanephric adenoma no specific changes,
+ 7, + 17, - Y (1 reported case)
density of the lesions (Simonnet et al.,
2002), and according to some reports,
rearrangements of mitochondrial DNA
(Kovacs et al., 1989).
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Development of high-throughput
methods for molecular profiling may provide
means for more accurate diagnosis of renal
tumors in the future. Based on the
comprehensive molecular characterization of
these lesions, they could be clustered into
subtypes with distinct biological and clinical
characteristics. Recent studies have shown
that molecular profiles detected by array-
based CGH and gene expression analysis are
consistent with previous clinical,
histological, and molecular understanding of
these tumors. These methods could be
valuable in evaluation of disease prognosis
and in differentiation of tumors with highly
similar morphology (Moch et al., 1999; Boer
et al., 2001; Takahashi et al., 2001; Young et
al., 2001; Wilhelm et al., 2002).
2.2 Familial clear cell carcinoma
2.2.1 von Hippel-Lindau disease
von Hippel-Lindau disease is the most
common hereditary renal cancer syndrome.
It is characterized by predisposition to
vascular tumors of the retina and central
nervous system (CNS), clear cell renal
carcinoma, and pheochromocytomas. The
earliest reports on the hereditary nature of
r e t i n a l  a n g i o m a s  a n d  C N S
hemangioblastomas are from the beginning
of the 20 th century (von Hippel, 1904;
Lindau, 1927).  More  comple te
characterization of the disease was reported
later (Melmon and Rosen, 1964).
The most common and earliest
features of VHL are CNS hemangio-
blastomas and retinal angiomas, occurring in
approximately 60% of VHL patients. They
are diagnosed on average at ages 30 and 25
years, respectively (Maddock et al., 1996).
Hemangio-blastomas are usually located in
the cerebellar hemispheres, spinal cord, and
brain stem. Due to their space-occupying
nature, they cause severe morbidity and are
the predominant cause of death in VHL
patients together with renal cell carcinoma
(Maddock et al., 1996). Renal cell carcinoma
occurs in approximately 25-45% of VHL
patients and arises between the ages of 25
and 58 years (Maddock et al., 1996; Linehan
et al., 2002). Typically, tumors are multiple
and bilateral and display clear cell histology.
Pheochromocytomas ,  which  a re
catecholamine-producing tumors arising
most often in the adrenal medulla, are
diagnosed in about 15% of patients, and they
tend to cluster in some families. In addition,
VHL patients may develop renal and
pancreatic cysts, cystadenomas or islet cell
tumors of the pancreas, endolymphatic sac
tumors, and papillary cystadenomas of the
epididymis. Based on the occurrence of renal
cancer and pheochromocytoma, VHL has
been classified as VHL1 without
pheochromo-cytoma, VHL2A wi th
pheochromocytoma and with low risk of
renal cancer, VHL2B with pheochromo-
cytoma and high risk of renal cancer, and
VHL2C with pheo-chromocytoma only
(without any other benign or malignant
tumors).
The predisposing gene for VHL was
first mapped to 3p25-p26 (Seizinger et al.,
1988) and then positionally cloned (Latif et
al., 1993). The VHL gene is comprised of
three exons and encodes two transcripts.
Characteristic germline mutations have later
been identified for the different cancer
phenotypes. Missense mutations associate
with pheochromo-cytoma (VHL2A,
VHL2B, VHL2C), whereas deletions and
truncating mutations are linked with renal
cell carinoma (VHL1) (Crossey et al.,
1994b; Chen et al., 1995; Zbar et al., 1996).
Evidence for VHL  being a tumor
suppressor gene was found in molecular
genetic analyses of tumors from VHL
patients displaying two inactivated alleles of
the gene (Crossey et al., 1994a) and in
subsequent functional analyses (Iliopoulos et
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al., 1995). The VHL protein is involved in
regulation of cellular responses to hypoxia
by targeting the hypoxia inducible factor 1_
(HIF-1_)  to  pro teosome-media ted
degradation in the presence of oxygen
(Iliopoulos et al., 1996; Maxwell et al.,
1999). HIF-1_ is a subunit of heterodimeric
transcription factor HIF-1, which binds to
hypoxia response elements (HREs) and
activates the expression of several genes
including proangiogenic factors and
glycolytic enzymes. Mutations in VHL
prevent ubiquitylation and degradation of
HIF-1_, resulting in accumulation of HIF-1_
and continuous activation of hypoxia
response genes. VHL has also been
implicated in control of the cell cycle exit
(Pause et al., 1998), fibronectin assembly,
and extracellular matrix formation (Ohh et
al., 1998).
2.2.2 Familial clear cell carcinoma with
constitutional translocation
A family segregating clear cell renal
carcinoma and a balanced translocation
t(3;8)(p14;q24) was described over twenty
years ago (Cohen et al., 1979). The genes
located in the translocation breakpoints,
FHIT and TRC8, were later isolated (Ohta et
al., 1996; Gemmill et al., 1998), but their
role in development of renal cell carcinoma
in this family has remained controversial.
Tumors from several families with different
chromosome 3 constitutional translocations
have later been analyzed and an alternative
mechanism involving VHL inactivation has
been suggested. Namely, tumors displayed
loss of the derivative chromosome harboring
the VHL gene and harbored mutations in the
remaining VHL allele (Schmidt et al., 1995;
Bodmer et al., 1998; Kanayama et al., 2001).
2.3 Familial papillary renal cell carcinoma
2.3.1 Hereditary papillary renal cell
carcinoma
Hereditary papillary renal cell carcinoma
(HPRC) is a rare dominantly inherited
condition characterized by predisposition to
multiple bilateral papillary renal cell tumors
(Zbar et al., 1994, 1995). The carcinomas
exhibit type 1 papillary histology with small
cells, low-grade basophilic nuclei (mainly
Fuhrman grades 1-2), and inconspicuous
amphophilic cytoplasm and nucleoli
(Lubensky et al., 1999). In the disease
families, some individuals have also been
affected with nonrenal malignancies, but any
association with predisposition to renal cell
carcinoma has remained obscure (Zbar et al.,
1995).
The disease gene was mapped to
7q31-q34 by linkage analysis in the HPRC
families, and germline mutations were
identified in the tyrosine-kinase domain of
the MET proto-oncogene (Schmidt et al.,
1997). Trisomy of chromosome 7 had
previously been observed in sporadic
papillary renal cell carcinomas (Kovacs,
1993) and renal cell carcinomas from
members of HPRC families (Schmidt et al.,
1997). The mutant allele was subsequently
demonstrated to be duplicated and
overexpressed in the tumors (Fischer et al.,
1998). M E T  encodes a tyrosine-kinase
receptor whose ligand is the hepatocyte
growth/scatter factor (HGF) (Bottaro et al.,
1991). Cells expressing mutant MET were
shown to display enhanced kinase activity,
be tumorigenic in nude mice, and introduce
invasive and metastatic properties in cell
lines and mice (Giordano et al., 1997; Jeffers
et al., 1997; Jeffers et al., 1998).
2.3.2 Familial papillary renal cell carcinoma
associated with papillary thyroid carcinoma
Occurrence of papillary thyroid cancer,
nodular thyroid disease, and tumors of the
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kidney has been reported in one large family
(Malchoff et al., 2000). Renal neoplasms
included one papillary renal cell carcinoma,
multifocal papillary adenomas, and renal
oncocytoma. After exclusion of the MET
gene, the condition was mapped to 1q21.
2.4 Other familial renal tumor syndromes
2.4.1 Tuberous sclerosis
Tuberous sclerosis (TS) is a dominantly
inherited disease characterized by multiple
hamartomas in different organs. The clinical
manifestations, including learning disability,
epilepsy and behavioral problems, are
caused by CNS lesions. TS is genetically
heterogeneous disease with two main
predisposing genes, TSC1 at 9q34 and TSC2
at 16p13 (Consortium TECTS, 1993; van
Slegtenhorst et al., 1997). The most common
renal manifestations are angiomyolipomas,
which despite their benign nature, can cause
severe morbidity due to hemorrhage or
compression of healthy renal tissue
(Iliopoulos and Eng, 2000). On rare
occasions, malignant renal tumors can be
detected. These are most often clear cell
carcinomas, although other histological
types have also been observed (Sampson et
al., 1995; Sampson, 1996). Renal carcinoma
is more frequent in the animal model of the
disease, the rat with germline mutations in
Tsc2 (Ecker rat). These animals also develop
tumors of the pituitary, spleen, and uterus.
Thus, the phenotype differs from the human
one (Yeung et al., 1994; Everitt et al., 1995;
Kobayashi et al., 1995).
2.4.2 Birt-Hogg-Dubé syndrome
Birt-Hogg-Dubé syndrome (BHD) is
characterized by three types of cutaneous
l e s ions ,  i . e .  f i b ro fo l l i cu lomas ,
trichodiscomas, and acrochordons
(Takahashi et al., 2002). Renal lesions in
BHD include variable histologic subtypes
such as oncocytomas, chromophobe and
papillary renal cell carcinomas, and clear
cell carcinomas (Toro et al., 1999). The gene
for BHD was localized to 17p11 (Schmidt et
al., 2001), and recently, the disease gene was
cloned (Nickerson et al., 2002). The gene
sequence predicts a novel protein that is
highly conserved in evolution but has no
homology to any known proteins.
2.4.3 Other hereditary conditions associated
with renal neoplasms
Renal cell carcinoma may also be associated
with hereditary nonpolyposis colorectal
cancer (HNPCC) and hyperparathyroidism-
jaw tumor syndrome (HPT-JT).
In HNPCC, which is caused by
germline mutations in the mismatch repair
genes, the most common manifestations are
colorectal and endometrial cancers. Affected
individuals also have an increased risk of
transitional cell cancer of the renal pelvis
and ureters, and other malignancies, such as
cancers of the stomach, small intestine,
ovaries, and hepatobiliary tract (Lynch and
Lynch, 2000).
HPT-JT is an autosomal dominant
disorder typified by primary hyperpara-
thyreoidism caused by parathyroid
adenomas. The disease is associated with
ossifying fibroma of the jaw and different
types of renal lesions including benign cysts,
hamartomas, Wilm’s tumor, and bilateral
papillary carcinoma (Haven et al., 2000).
HPT-JT is linked to 1q21-q31 (Szabo et al.,
1995).
3. UTERINE SMOOTH MUSCLE TUMORS
3.1 Uterine leiomyomas
3.1.1 Clinical and histopathological features
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Uterine leiomyomas (myomas or fibroids)
are the most common tumors in
premenopausal women. They are clinically
evident in 25% of women (Zaloudek and
Norris, 1994), but by careful pathological
examination of surgical specimens, they can
be diagnosed in up to 77% of women
(Cramer and Patel, 1990). Although
leiomyomas are benign tumors, they have a
major impact on women’s health by causing
numerous symptoms, being associated with
infertility, and being the leading cause of
hysterectomy.
Leiomyomas arise from the uterine
smooth muscle cells or their progenitors in
submucosal, intramural, and subserosal
locations. Leiomyomas are roughly
spherical, well-circumscribed lesions with a
firm fibrous appearance. Histologically, they
are composed of interlacing bundles of
elongated, eosinophilic smooth muscle cells
surrounded by well-vascularized connective
tissue (Crow, 1998; Robboy et al., 2000).
Typically, tumor cells have cigar-shaped
nuclei, and mitoses are rarely detected in the
lesions. In addition to the usual appearance
of leiomyomas, a number of variant forms
exist. Cellular leiomyomas have a higher
density of smooth muscle cells, and atypical
leiomyomas are characterized by cells with
pleomorphic nuclei and often giant cells.
Epithelioid leiomyomas are composed of
polygonal rather than spindle cells, and
lipoleiomyomas contain a variable amount
of adipose tissue. In addition, some
leiomyomas may harbor degenerative
changes such as hyalinization, calcification,
and red degeneration. Calcification is often
detected postmenopausally, whereas red
degeneration commonly occurs during
pregnancy. In rare cases, leiomyomas may
have unusual growth patterns. These entities
include intravascular leiomyomatosis,
benign metastasizing leiomyoma,
disseminated peritoneal leiomyomatosis,
lymphangioleiomyoma-tosis, and diffuse
leiomyomatosis (Robboy et al., 2000).
Leiomyomas cause variable
symptoms, which are mainly dependent on
the location and size of the lesions.
Abnormal or prolonged bleeding is
commonly caused by submucosal
leiomyomas, acute pain can indicate torsion
of a pedunculated tumor, and urinary
symptoms are usually the result of anterior
and constipation by posterior lesions. During
pregnancy uterine leiomyomas typically
enlarge and are associated with
complications such as miscarriage, placental
abruption, and premature labor (Stewart,
2001).
The diagnosis of uterine leiomyomas
is generally based on clinical pelvic
e x a m i n a t i o n  a n d  t r a n s v a g i n a l
ultrasonography. Ultrasonography is as good
as magnetic resonance imaging (MRI) in
detection of leiomyomas, but MRI may
provide advantages in determining tumor
location (Dueholm et al., 2002). The
treatment of leiomyomas depends on their
size and location, the presenting symptoms,
and the age and reproductive desires of the
patient. Surgical procedures, including
myomectomy and hysterectomy, are widely
used. For patients who desire future
pregnancies myomectomy is an option, but
recurrent myomas often develop after the
procedure. Due to risk of complications,
such as infections, hemorrhage, and bowel
or ureteric injury in patients undergoing
hysterectomy (Takamizawa et al., 1998),
new surgical (hysteroscopic removal,
endometrial ablation, arterial embolization)
and nonsurgical (GnRH agonists or
antisteroid compounds) methods have been
developed (Stewart, 2001; Walker et al.,
2002).
3.1.2 Etiology and pathogenesis
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The etiology and pathogenesis of uterine
leiomyomas are poorly understood.
However, estrogen and progesterone play a
role in their development; leiomyomas are
not seen before puberty, they increase in size
dur ing  pregnancy ,  and  shr ink
postmenopausally and after treatment with
GnRH agonists (Morton,  1998).
Leiomyomas have been observed to display
increased expression of both estrogen and
progesterone receptors. This is proposed to
lead to increased end-organ sensitivity to
these hormones (Brandon et al., 1993, 1995).
Progesterone has been suggested to be one
of the major factors contributing to
leiomyoma growth; when progesterone
levels are high, as in the luteal phase of the
menstrual cycle, mitotic activity in
leiomyomas is elevated (Kawaguchi et al.,
1989). Similarly, leiomyomas tend to
enlarge during pregnancy when progesterone
levels are increased.
In addition to ovarian steroid
hormones, several growth factors have been
implicated in the pathogenesis of
leiomyomas. Expression of either growth
factors or their receptors has been observed
to be higher in leiomyomas than in
corresponding normal myometrium
(Andersen, 1998). Factors involved include
insulin-like growth factors (IGF-I, IGF-II),
epidermal growth factor (EGF), platelet-
derived growth factor (PDGF), and their
receptors. In a recent cDNA array analysis
of uterine leiomyomas, IGF-II was one of
the overexpressed genes in tumors as
compared with normal myometrium (Tsibris
et al., 2002). This and other studies have also
demonstrated elevated mRNA levels of
components in the Wnt signaling pathway,
including frizzled and secreted frizzled
related protein 1 (sFRP1) (Fukuhara et al.,
2002; Tsibris et al., 2002). Aberrations in the
Wnt signaling pathway have previously been
implicated in the pathology of human
neoplasms, including colorectal carcinoma
(Taipale and Beachy, 2001).
Genetic predisposition to uterine
leiomyomas has been proposed based on
case reports of disease families (Vikhlyaeva
et al., 1995), but inherited genetic defects
have not been identified. Compared with
malignant neoplasms, leiomyomas appear to
display fewer chromosomal aberrations.
However, about 40% of these tumors harbor
chromosomal alterations. The most frequent
changes include translocation involving
chromosomes 12 and 14, rearrangements in
6p, and deletion of 7q (Nilbert et al., 1990a;
Morton, 1998; Ligon and Morton, 2000). In
addition, chromosome 1 alterations, losses
on chromosome 4, and gains on
chromosomes 9, 12, 14, and 19 have been
observed, among others (Packenham et al.,
1997; Levy et al., 2000). Studies on the
genes located at the breakpoints in
chromosomes 12, 14, and 6 have led to
identification of genes HMGIC at 12q15 and
HMGIY at 6p21. The gene products belong
to a family of high-mobility-group proteins
which play a role in transcription regulation
and chromatin organization. Alterations of
HMGIC and HMGIY have been observed in
several tumor types of mesenchymal origin
including leiomyomas (Schoenmakers et al.,
1995; Kazmierczak et al., 1998; Mine et al.,
2001). In chromosome 14, the RAD51B gene
has been identified and suggested to play a
role in tumorigenesis and convey tissue-
specificity in leiomyomas with translocation
t(12;14) (Schoenmakers et al., 1999).
RAD51B belongs to a family of genes highly
similar to bacterial RecA and S. cerevisiae
Rad51, which are known to be involved in
homologous recombination and repair.
Observations of 7q losses detected by
cytogenetic analyses have been supported by
several studies on allelic loss by
microsatellite markers (Ishwad et al., 1995,
1997; Vanni et al., 1997, 1999; van der
Heijden et al., 1998; Mao et al., 1999). In a
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genome-wide microsatellite marker analysis
of allelic loss, 7q was the only locus
displaying frequent LOH (Mao et al., 1999).
3.2 Uterine leiomyosarcoma
Leiomyosarcoma is a malignant
mesenchymal neoplasm with smooth muscle
differentiation. Tumors typically display
spindle cells with blunt-ended nuclei and
eosinophilic cytoplasm and stain positive for
_-smooth muscle actin and desmin.
Leiomyosarcoma can occur in a variety of
anatomical  s i tes ,  including the
retroperitoneum, skin, extremities, and
uterus (Enzinger and Weiss, 1995). Uterine
leiomyosarcoma comprises approximately
one-fourth of uterine sarcomas, which
constitute 3% of uterine malignancies. Other
uterine sarcomas include endo-metrial
stromal sarcoma, malignant mixed müllerian
tumor, and müllerian adeno-sarcoma (Rosai,
1996). Uterine leiomyo-sarcomas usually
occur during menopause in women over the
age of 40 (Barbieri and Andersen, 1992) and
are aggressive tumors with a five-year
survival rate of 40% (Kumar et al., 1997).
Typically, gross appearance of
leiomyosarcomas differs from that of uterine
leiomyomas. Leiomyosarcomas invade the
adjacent myometrium, are not demarcated
from normal tissue, and contain areas with
necroses and hemorrhages. Histologically,
the tumors are densely cellular and display
cells with a variable degree of
differentiation. Diagnostic difficulties may
be encountered when benign leiomyomas
display unusual features resembling
leiomyosarcoma (Wilkinson and Rollason,
2001). Features utilized in differential
diagnosis include mitotic activity, nuclear
atypia, coagulative necrosis, degree of
cellularity and differentiation, presence of
giant cells, and invasion to blood vessels and
adjacent myometrium (Robboy et al., 2000).
Previously, the value of mitotic activity was
emphasized, and the threshold for diagnosis
of leiomyosarcoma was set at 10 mitoses per
10 high-power-field. However, by taking
into account all relevant features, tumors that
are clearly benign or malignant as well as
those in the intermediate group can be
classified more accurately.
In contrast to leiomyomas,
leiomyosarcomas are characterized by a
wide range of chromosomal anomalies.
These involve chromosomes 1, 3, 6, 7, 10,
11, 17, and 19 (Nilbert et al., 1990; Iliszko et
al., 1998). By CGH analyses, many
alterations, such as gains of chromosomes 1,
8, 10, 17, and Xp, and losses of 1p, 10q, 13q,
14q, and 22q, have been detected
(Packenham et al., 1997; Levy et al., 2000).
Due to overlap in morphologic phenotypes
between uterine leiomyo-sarcomas and
leiomyomas,  the  hypothesis  of
leiomyosarcoma arising from pre-existing
leiomyoma has been raised. Some estimates
propose that 0.1% of benign uterine
leiomyomas would progress to malignancy
(Morton, 1998). However, evidence for the
progression could not be demonstrated by
CGH and LOH analyses as no specific
changes common to both tumor types were
apparent (Packenham et al., 1997; Quade et
al., 1999; Levy et al., 2000).
3.3 Hereditary multiple cutaneous and
uterine leiomyomatosis (MCL)
Multiple cutaneous and uterine
leiomyomatosis (MCL) is an autosomal
dominant disorder characterized by
development of leiomyomata of the skin and
the uterus (fibroids) in affected individuals.
Leiomyomas of the skin are rare benign
tumors thought to originate from the
arrectores pilorum muscle of the hair follicle
(Virchow, 1854). They are smooth,
erythematous nodules of 0.2-2 cm in
diameter and usually appear on the face,
back, and extensor surfaces of the
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extremities. They are often painful and
sensitive to cold and touch (Spencer and
Amonette, 1996). Histologically, these
lesions, also called piloleiomyomas, are
composed of interlacing bundles of smooth
muscle cells and are sometimes difficult to
identify (Spencer and Amonette, 1996).
These tumors appear to be equally common
in men and women (Raj et al., 1997).
Although estrogen and progesterone have
been implicated in the development of
uterine and some extrauterine smooth
muscle tumors, leiomyomas of the skin have
not been reported to express elevated levels
of estrogen or progesterone receptors
(McGinley et al., 1997).
The first report on inherited
susceptibility to cutaneous leiomyomas was
based on a family with several affected
individuals (Kloepfer et al., 1958). An
association with uterine leiomyomas in
affected women was later proposed
(Mezzadra, 1965; Reed et al., 1973; Jolliffe,
1978; Engelke and Christophers, 1979;
Thyresson and Su, 1981; Garcia Muret et al.,
1988; Fernandez-Pugnaire and Delgado-
Florencio, 1995; Vellanki et al., 1996). An
autosomal dominant inheritance of the
condition was suggested by examination of
pedigrees, but details on the molecular basis
of the disease remained unclear. The only
proposed susceptibility locus for MCL,
18p11, was based on observations of
multiple cutaneous leiomyomata in a woman
with 9p trisomy/18pter monosomy (Fryns et
a l . ,  1 9 8 5 ) .
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AIMS OF THE STUDY
1. To characterize the main clinical features of hereditary leiomyomatosis and renal cell
cancer (HLRCC) families.
2. To characterize the main histopathological and molecular features of HLRCC tumors.
3. To localize the gene predisposing to HLRCC.
4. To identify the gene predisposing to HLRCC and the mutations causing the disease.
5. To investigate the role of the HLRCC gene in sporadic tumor types associated with the
HLRCC phenotype.
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MATERIALS AND METHODS
1. PATIENTS AND TUMOR SAMPLES
1.1 Families and clinical documentation (I,
II)
The proband (FAM-1/IV-7; see Figure 1 in
Study I) of a large kindred (FAM-1) was
given genetic counseling at the Department
of Clinical Genetics, Oulu University
Hospital, Oulu, because her mother (FAM-
1/III-9) and one of her sisters (FAM-1/IV-4)
had been affected with renal cell carcinoma
at the relatively early ages of 48 and 44
years, respectively. To obtain a documented
disease history of the family, data were
collected by patient interviews, examination
of patient records, and identification of the
proband’s relatives from the official
population registries followed by their tumor
status verification through patient records
and the Finnish Cancer Registry. The Cancer
Registry covers the cancer cases in the
Finnish population almost completely and
with good accuracy (Kyllönen et al., 1987;
Teppo et al., 1994). Altogether four
individuals in FAM-1 were diagnosed with
early-onset renal cell carcinoma. The family
also included seventeen individuals with
leiomyomas of the uterus and/or skin, and
two with uterine leiomyosarcoma.
To identify additional families with a
phenotype similar to FAM-1, a search of
renal cancer patients between the ages of 15
and 35 years was carried out utilizing the
Cancer Registry data. As a result of the
search, histology of tumor slides from 27
patients was examined to identify lesions
with the same distinct features as in
carcinomas from FAM-1. This effort led to
recognition of the second family (FAM-2;
see Figure 1 in Study I), which included two
siblings diagnosed with renal cell carcinoma
at the ages of 32 (FAM-2/II-2) and 26
(FAM-2/II-3) and one with multiple uterine
leiomyomas at the age of 41 (FAM-2/II-1).
The third family (FAM-3; see Figure
1 in Study II) was originally diagnosed with
mult iple  cutaneous and uter ine
leiomyomatosis (MCL) at the Department of
Clinical Genetics at Turku University
Hospital, Turku. Detailed disease history of
the family was derived through patient
interviews, and investigation of patient
records, population registries, and Cancer
Registry data. The family included seven
individuals with cutaneous leiomyomas and
three with leiomyomas of the uterus.
In addition to the three Finnish
families, 39 families from the UK were
included in the study (III) through
collaboration with Drs. Ian Tomlinson
(Imperial Cancer Research Fund, London,
UK) and Richard Houlston (Institute of
Cancer Research, Sutton, Surrey, UK).
These families had a typical MCL phenotype
with leiomyomata of the uterus and skin
(Alam et al., 2001). Predisposition to renal
cancer was not observed.
This study was approved by the
authorized ethics review committee of the
Joint Authority for the Hospital District of
Helsinki and Uusimaa (HUS).
1.2 Cancer-free control individuals (IV)
Blood samples from anonymous cancer-free
individuals were obtained from the Finnish
Red Cross, Helsinki. DNA from the control
individuals was used in Study IV to examine
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the Finnish population frequencies of two
germline mutations observed in the FH gene.
1.3 Tumor samples (I, II, III, IV, unpublished
data)
Tumors from HLRCC patients were
analyzed for LOH (I, II, unpublished data)
and/or mutations in the FH gene (III,
unpublished data). Tumors included seven
renal cell carcinomas (from patients FAM-
1/III-7, FAM-1/III-9, FAM-1/IV-4, FAM-
1/IV-11, FAM-2/II-2, FAM-2/II-3, FAM-
3/II-4), seven uterine leiomyomas (from
patients FAM-1/III-1, FAM-1/III-3, FAM-
1/III-4, FAM-1/III-7, FAM-2/II-1, FAM-
3/II-4), seven cutaneous leiomyomas (from
patient FAM-3/III-5), and one uterine
leiomyosarcoma (from patient FAM-1/III-
13).
Sporadic tumors from individuals
with no known family history of cancer were
also studied for LOH at the HLRCC locus
(II, unpublished data) and mutations in the
FH gene (IV). Samples included 10
cutaneous leiomyomas (II, IV), 41 uterine
leiomyomas (26 in Study II and 41 in Study
IV), 58 renal cell carcinomas (IV, an
unpublished study), 18 uterine leiomyo-
sarcomas (IV, an unpublished study), 35
sarcomas (IV), 29 prostate carcinomas (IV),
and 15 lobular breast carcinomas (IV). Renal
cell carcinomas included 40 clear cell
carcinomas, 4 papillary type 1 tumors, and
11 papillary type 2 tumors, and 3 other
tumors. Sarcomas included 2 extrauterine
leiomyosarcomas, 5 malignant fibrous
histiocytomas, 2 chondrosarcomas, 1
fibrosarcoma, 9 liposarcomas, 4 osteo-
sarcomas, 1 Ewing’s sarcoma, and 11
sarcomas of undefined histology.
1.4 DNA and RNA extraction (I, II, III, IV)
DNA from blood samples and cell lines of
HLRCC patients, fresh-frozen tumor
samples, and blood samples of control
individuals was extracted using standard
procedures (Lahiri and Nurnberger, 1991).
Informed consent was obtained from all
patients. DNA extraction from the paraffin-
embedded tumor and normal tissues was
carried out using deparaffinization with
xylene, washing with ethanol, treatment with
proteinase K, and extraction with phenol and
chloroform (Kannio et al., 1996).
Examination of histology and dissection of
tumor samples were performed to confirm
the histology and to obtain the maximum
amount of tumor tissue for subsequent
analyses of the tumor DNA. Total cellular
RNA from two cancer-free control
individuals and fresh-frozen normal
myometrium was extracted using the
RNeasy kit (Qiagen).
2. HISTOPATHOLOGICAL EVALUATION (I,
II)
Paraffin-embedded t issue blocks,
hematoxylin/eosin (H&E) –stained slides,
and pathologists’ gross reports for the seven
renal cell carcinomas (from patients FAM-
1/III-7, FAM-1/III-9, FAM-1/IV-4, FAM-
1/IV-11, FAM-2/II-2, FAM-2/II-3, FAM-
3/II-4) were obtained for histopathological
analyses from the Departments of Pathology
at Oulu University Hospital, Helsinki
University Central Hospital, and Turku
University Hospital. The tumors were
classified according to the terms of the
Armed Forces Institute of Pathology
classification (Murphy et al., 1994), and the
tumor histopathology was compared with
criteria for papillary renal cell carcinoma
proposed by Delahunt and Eble (1997).
H&E staining and immunohisto-chemistry
for epithelial membrane antigen (EMA),
vimentin, cytokeratin 7 (CK7), and human
milk fat globule (HMFG1 and HMFG2)
were performed on all tumors.
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In addition to renal tumors, paraffin-
embedded tissue blocks and/or H&E slides
from the following tumors were obtained for
histopathological re-evaluation: from FAM-
1, two uterine leiomyomas (from patients
FAM-1/III-12 and FAM-1/III-13), two
cutaneous leiomyomas (from patients FAM-
1/III-12 and FAM-1/III-13), metastases
(ovaries, omentum, para-aortic and
clavicular lymph nodes) of a cancer of
unknown origin (from patient FAM-1/III-5),
one breast cancer (from patient FAM-1/III-
13), and one bladder cancer (from patient
FAM-1/III-10); from FAM-3, seven
cutaneous leiomyomas (from patient FAM-
3/III-5) and two uterine tumors (from patient
FAM-3/I-1).
3. COMPARATIVE GENOMIC
HYBRIDIZATION (CGH) (UNPUBLISHED
DATA)
Comparative genomic hybridization (CGH)
was performed on seven renal cell
carcinomas from families FAM-1, FAM-2,
and FAM-3 to investigate the genetic profile
of these tumors. Standard methods described
by Kallioniemi et al. (1992) were used. The
analysis was performed in the laboratory of
Professor Jorma Isola (Institute of Medical
Technology, Tampere, Finland).
4. MAPPING OF THE DISEASE LOCUS
4.1 Microsatellite marker analysis (I, II, III)
To exclude MET and VHL as predisposing
genes for the phenotype seen in FAM-1,
genotyping of four renal cell carcinoma
patients from FAM-1 was carried out by
microsatellite markers spanning the
respective loci. After demonstrating negative
linkage at these loci, a genome-wide search
with Perkin-Elmer Applied Biosystems
PRISM Linkage Mapping Set MD-10 (P/N
450067, 10 cM density) containing 370
markers was performed in FAM-1. PCR
amplicons were run on an Applied
Biosystems PRISM 377 DNA sequencer
(Applied Biosystems) and data analyzed by
using Genescan 3.1 software (Applied
Biosystems). To confirm the results of the
genome-wide search, additional genotyping
was carried out at the most positive locus.
Twelve markers located in 1q42-q44 were
analyzed in FAM-1, FAM-2, and FAM-3.
To reduce the target area, markers from the
commercial sets and 28 novel short tandem
repeats were used for genotyping in Study
III.
4.2 Linkage analysis and haplotype
construction (I, II, III)
All linkage analyses were performed by
using the GENEHUNTER (Kruglyak et al.,
1996) and FASTLINK (Cottingham et al.,
1993) programs. In addition, a modified
MLINK program of the Fastlinkage package
LMLINK (Rohde et al., 1995) was used to
include the LOH data of Study I in the
linkage analysis. When analyzing the data
obtained from the genome-wide search, the
FAM-1 pedigree was divided into two due to
its large size to enable multipoint linkage
analysis by the GENEHUNTER program.
The chromosomal regions displaying lod
score 1 or higher were then reanalyzed with
the combined pedigree structure. When
analyzing the genotyping data from FAM-1
and FAM-2, dominant inheritance for the
tumor predisposition phenotype was
presumed and penetrance was conservatively
estimated to be 0.4. Individuals with
cutaneous nodules/ leiomyomas, uterine
leiomyomas, and renal cell carcinoma were
considered to be affected. Probabilities for
phenocopies were set at 0.002 for
leiomyomas of the skin, 0.2 for uterine
leiomyomas, and 0.00001 for renal cell
carcinoma. For subsequent analysis of FAM-
3, penetrance was estimated to be 0.8.
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The most likely haplotypes assuming
the minimum number of recombinations
were manually constructed in the
chromosomal regions displaying lod score 1
or higher in the genome-wide linkage
analysis in FAM-1. Haplotype construction
was also carried out when narrowing the
final target region.
4.3 Identification of novel short tandem
repeats (III)
Short tandem repeats were identified at the
HLRCC  locus by inspection of the draft
genome sequence of BAC clones (Sanger
Centre Institute, 2001) and by BLAST
searches (NCBI Blast, 2001). Primers for
PCR were designed utilizing the Primer3
server (Primer3 Server, 2002) to amplify
100-250 bp fragments containing the
microsatellite sequences.
4.4 Fluorescence in situ hybridization
(FISH) analysis (III)
Due to observations on predisposition to
renal cancer only in the Finnish HLRCC
families and non-mendelian inheritance of
microsatellite alleles in two UK pedigrees,
fluorescence in situ hybridization (FISH)
analysis was carried out in the laboratory of
Dr. Ian Tomlinson to detect putative large
germline deletions. Metaphase spreads of
lymphoblast cell lines from probands of
Finnish families FAM-1 and FAM-2, and
UK families 207 and 713 were prepared by
standard protocols. BAC clones in the target
region were fluorescently labeled by nick
translation with Fluoro Green, Fluoro Red,
and Cy5-sUTP (Amersham Phamacia
Biotech), and were hybridized overnight to
the metaphase spreads under competitive
conditions. Slides were washed and
counterstained with 4,6-diamidino-2-
phenyindole (DAPI). Images were acquired
using a cooled charge-coupled camera
(Photometrics) attached to a Zeiss Axioplan
2 Imaging Microscope and SmartCapture 2
software (Applied Imaging).
5. LOSS OF HETEROZYGOSITY ANALYSIS
(LOH) (I, II, UNPUBLISHED DATA)
LOH analysis by microsatellite markers was
performed on the available tumors from the
HLRCC families to confirm the linkage of
HLRCC to 1q42-q44 (I, II), to narrow the
target region containing the HLRCC gene
(III), and to investigate the characteristics of
the HLRCC  gene (I, II). Seven uterine
leiomyomas, seven cutaneous leiomyomas,
seven renal cell carcinomas, and one uterine
leiomyosarcoma were included in the
analyses (I, II, unpublished data). Eighteen
polymorphic microsatellite markers
spanning the HLRCC locus were used to
amplify the tumor and normal tissue DNA
from HLRCC patients.
LOH analysis was also carried out on
sporadic forms of tumor types associated
with the HLRCC phenotype to evaluate the
involvement of the HLRCC locus in sporadic
tumorigenesis (unpublished data). Samples
genotyped with markers DIS517, DIS547,
and D1S423 included 10 cutaneous
leiomyomas, 26 uterine leiomyomas, 18
uterine leiomyosarcomas, and 58 renal cell
carcinomas with corresponding normal
tissues.
Electrophoresis and subsequent data
analysis in all LOH analyses were performed
as described in section 4.1. Allele loss was
scored if the area under an allele peak was
reduced to <40% of its original value
(Canzian et al., 1996).
6. MUTATION SCREENING
6.1 Identification of known and predicted
transcripts (III)
Materials and methods
33
The genomic sequence used in the gene
predictions was obtained from the
chromosome 1 physical map published by
the Sanger Centre Institute (2001). Nucleic
acid identification program (NIX, 2001),
NCBI Entrez Genome Map Viewer (2001),
and Ensembl Human Genome Server (2001)
were used to identify known genes, ESTs,
and putative novel genes in the target region.
Exon-intron boundaries of the candidate
sequences were determined by BLAST
searches and verification of expression of a
gene prediction was performed by RT-PCR
from human total mRNA derived from two
cancer-free control individuals (Qiagen
RNEasy).
6.2 Sequencing (III, IV)
To identify the disease-predisposing gene,
mutation screening of 6 known genes
(RGS7, FH, KMO, OPN3, CHML, EXO1)
and 41 positional candidate sequences was
performed by sequencing of genomic DNA
of probands from 42 families (3 from
Finland and 39 from the UK) (III). In the
collaborative groups, mutation analyses were
performed by single-strand conformational
polymorphism (SSCP) and conformation-
specific gel electrophoresis (CSGE). In
Study IV, sporadic tumors were analyzed for
FH mutations by genomic sequencing.
All PCR primers were designed
utilizing the Primer3 server (2002) to
amplify known or predicted exons and the
flanking intronic sequence. PCR reactions
were carried out in a 50-_ l reaction volume
containing 100 ng of genomic DNA, 1X
PCR buffer (Applied Biosystems), 300 _ M
of each dNTP (Finnzymes), 1 _ M of
forward and reverse primers, and 2.5 units of
AmpliTaqGOLD polymerase (Applied
Biosystems). For different exons, optimal
MgCl2 concentrations and annealing
temperatures were between 1.5 mM and 3.0
mM, and 56_ C and 64_ C, respectively. The
following general cycling conditions were
used: 10 min at 95_ C, then 35 cycles of
denaturation at 95_ C for 45 s, annealing at a
corresponding temperature for 1 min,
elongation at 72_ C for 1 min, and final
extension at 72_ C for 10 min. The PCR
product (5 _ l) was run on an agarose gel to
verify the specificity of the reaction, and the
rest of the product was purified using the
NucleoSpin PCR purification kit (Macherey-
Nagel). Direct sequencing of PCR products
was performed using BigDye3 termination
chemistry (Applied Biosystems) with the
ABI 3100 Genetic Analyzer (Applied
Biosystems) according to the manufacturer’s
instructions. All sequence changes were
verified by reamplification of the
corresponding PCR fragment and
sequencing of both DNA strands.
6.3 Reverse transcriptase polymerase chain
reaction (RT-PCR) and mRNA expression
analysis (III)
Expression levels of F H in human tissues
(smooth muscle, brain, heart, kidney, liver,
lung, pancreas, placenta, skeletal muscle,
colon, ovary, peripheral blood leukocyte,
prostate, small intestine, spleen, testis,
thymus) were measured by using RT-PCR.
mRNA from smooth muscle was obtained
from the normal myometrium of a
hysterectomized patient (Qiagen RNEasy),
and cDNA was synthesized by reverse
transcription reaction (Promega). cDNA
from other tissues was provided by
Clontech. FH cDNA representing exons one
to five was amplified by PCR. G3PDH gene
was used as a control gene to compare
cDNA amplification levels. Samples were
run on agarose gel.
6.4 Single-strand conformational
polymorphism (SSCP) (IV)
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SSCP analysis was performed to investigate
the Finnish population frequency of a
putative Finnish founder mutation in F H
using DNA samples from 448 anonymous
cancer-free blood donors. The analysis was
performed utilizing MDE gel solution (FMC
BioProducts). PCR products were run on
0.6xMDE gels, 4W for 20 hours. The
running buffer was 0.6xTBE. SSCP gels
were silver-stained according to standard
procedures.
6.5 Denaturing high-performance liquid
chromatography (DHPLC) (IV)
To examine the population frequency of an
FH allele detected in the germline of a
patient with uterine leiomyosarcoma, DNA
from 134 controls was used. The amplicons
for the DHPLC analysis were generated in
50 _ l PCR reactions consisting of 50 ng of
genomic DNA, 0.7X Platinum PCR Buffer
(Invitrogen) 200 _ M of each dNTP
(Finnzymes), 0.3 _ M of forward and reverse
primers, 1.4 mM of MgCl2, and DNA
polymerases Platinum Taq (1.25 units;
Invitrogen), Titanium Taq (0.6 units;
Clontech), and AmpliTaq Gold (0.6 units;
Applied Biosystems). The hot-start PCR
cycling conditions were as follows: 94_ C
for 12 min, then 35 cycles of denaturing for
30 s, 58_ C for 30 s and 72_ C for 45 s, and
final extension at 72_ C for 10 min. The
denaturing temperature was lowered from
94_ C to 89_ C after 10 cycles. Samples
were denatured at 95_ C for 5 min and
reannealed by gradually cooling down
1_ C/min for 50 min. DHPLC heteroduplex
analysis was performed at 55_ C using
automated HPLC instrumentation with an
Eclipse dsDNA analytical column (Agilent
Technologies). The analytical gradient was
created by mixing buffer A (100 mM
triethylammonium acetate and 0.1 mM
EDTA) and 57.4-71.9% buffer B (100 nM
triethylammonium acetate, 0.1 mM EDTA
and 25% acetonitrile) at a flow rate of 0.4
ml/min.
7. ACTIVITY ASSAY FOR FUMARATE
HYDRATASE (III)
Fumarate hydratase enzyme activity was
measured in lymphoblastoid cell lines of
leiomyomatosis patients and spouse controls
from UK families and in patients’
leiomyomas as described by Hatch (1978).
These measurements were carried out in the
laboratory of Dr. Simon Olpin (Sheffield
Children’s Hospital, Sheffield, UK). Later,
the assay was also set up in our laboratory.
The assay is based on coupling of malate
production by FH to nicotinamide adenine
dinucleotide (NADP+) reduction via the
malic enzyme. Malate is formed from
fumarate by fumarate hydratase present in
the tissue/cell sonicate. Reduction of
NADP+ to NADPH occurs via the malic
enzyme in the conversion of malate to
pyruvate. The increase in absorbance at 340
nm due to formation of NADPH is then
measured. The linked assay starts with
fumarate (final concentration 10 mM), tissue
or lymphoblast sonicate, 25 mM HEPES-
KOH pH 7.5, 0.27 nM NADP+, 4 mM
MgCl2, 5 mM potassium phosphate, and 0.2
units/ml of purified malic enzyme (EC
1.1.1.40, Sigma).
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RESULTS
1. CLINICAL FEATURES OF HEREDITARY
LEIOMYOMATOSIS AND RENAL CELL
CANCER (HLRCC) (I, II)
The tumor predisposition in FAM-1,
including susceptibility to uterine and
cutaneous leiomyomas, renal cell carcinoma
and uterine leiomyosarcoma, appeared
dominantly inherited (see Table 4 for
summary of the features of affected
individuals) .  The most common
manifestation was multiple leiomyomas of
the uterus, which was diagnosed in 12
women in FAM-1 between the ages of 25
and 48 years. Two patients had been affected
with and operated on for malignant uterine
leiomyosarcoma at the ages of 35 (FAM-
1/III-9) and 40 (FAM-1/III-13). In addition,
a third patient (FAM-1/III-7) was suspected
of being affected with uterine
leiomyosarcoma based on ultrasonography,
but due to her general condition, an
operation was not performed, and thus, the
diagnosis remained unconfirmed. Eight
individuals, including both men and women,
had lesions on their skin. Two of these were
available for histopathological analysis and
were verified as leiomyomas. Renal cell
carcinoma occurred in four individuals
between the ages of 33 and 48. All the
patients had metastasized disease at the time
of diagnosis. They underwent nephrectomy
and received adjuvant treatment. Three of
the patients died 5 to 18 months after
diagnosis, and the fourth patient (FAM-
1/IV-4) died after six years due to relapse of
the cancer. In addition, patient FAM-1/III-10
had been diagnosed with bladder cancer at
the age of 65, and the patient with uterine
leiomyosarcoma (FAM-1/III-13) had been
affected with breast cancer and multiple
myeloma at the age of 61.
FAM-2 was identified by examining
tumor histology of young renal cancer
patients. One tumor in this series displayed a
similar histology to the tumors from FAM-1.
The patient (FAM-2/II-2) had been 33 years
old at the time of diagnosis and had a brother
(FAM-2/II-3) with renal cell carcinoma
diagnosed at age 26. Both patients died
within a year after cancer diagnosis. The
family included two other siblings. One
(FAM-2/II-1) had been operated on at the
age of 41 due to multiple uterine
leiomyomas, and recently, the other (FAM-
2/II-4) was diagnosed with the same
condition. The father of the family (FAM-
2/I-1) had been diagnosed with prostate
cancer at age 65.
FAM-3 included seven individuals
with cutaneous nodules. Lesions of three
patients were histologically verified as
leiomyomas. The proband (FAM-3/III-5)
had hundreds of leiomyomas on the skin of
his left arm, trunk, and left leg, some of
which were painful and were surgically
removed. The tumors were first observed
when the patient was 10 years old and a cast
covering his left arm from shoulder to wrist
was removed. Two individuals of FAM-3
were affected with leiomyomas of the uterus
at the ages of 23 (FAM-3/II-2) and 34
(FAM-3/II-4). In addition, one family
member (FAM-3/I-1) reported that she had
been operated on at the age of 27 due to
suspicion of uterine malignancy. Data from
the patient records and the Cancer Registry
revealed that patient FAM-3/I-1 was
diagnosed with uterine leiomyosarcoma at
age 27, patient FAM-
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Table 4. Phenotypes of all affected individuals in FAM-1, FAM-2, and FAM-3.
Individual1 Sex Skin lesions Uterine tumors RCC Other
neoplasms
FAM-1/II-1 F Cutaneous nodules No No No
FAM-1/II-3 F No Leiomyomas (40) No No
FAM-1/II-4 M Cutaneous nodules - No No
FAM-1/III-1 F No Leiomyomas (44) No No
FAM-1/III-2 F No Leiomyomas (48) No No
FAM-1/III-3 F No Leiomyomas (40) No No
FAM-1/III-4 F No Leiomyomas (34) No No
FAM-1/III-5 F No Leiomyomas (37) No Primary site
unknown (42)
FAM-1/III-7 F No Leiomyomas (39) Yes (39) No
FAM-1/III-9 F Cutaneous nodules Leiomyosarcoma (35) Yes (48) No
FAM-1/III-12 F Leiomyomas Leiomyomas (39) No No
FAM-1/III-13 F Leiomyomas Leiomyomas, leiomyosarcoma (40) No Breast
carcinoma (61),
multiple
myeloma (61)
FAM-1/III-14 M Cutaneous nodules - No No
FAM-1/IV-4 F No Leiomyomas (29) Yes (42) No
FAM-1/IV-11 F Cutaneous nodules No Yes (33)
FAM-1/IV-14 F No Leiomyomas (25) No No
FAM-1/IV-16 F Leiomyomas Leiomyomas (33) No No
FAM-2/I-1 M No - No Prostate cancer
(65)
FAM-2/II-1 F No Leiomyomas (41) No No
FAM-2/II-2 F No No Yes (33) No
FAM-2/II-3 M No - Yes (26) No
FAM-2/II-4 F No Leiomyomas (40) No No
FAM-3/I-1 F Leiomyomas (31) Leiomyomas (typical&symplastic)
(27)
No No
FAM-3/I-3 M Cutaneous nodules - No No
FAM-3/II-2 F Cutaneous nodules Leiomyomas (23) No No
FAM-3/II-4 F Cutaneous nodules Leiomyomas (34) Yes (35) No
FAM-3/II-5 M Leiomyomas (35) - No No
FAM-3/III-1 F Leiomyomas (28) No No No
FAM-3/III-5 M Leiomyomas (10) - No No
1 All listed individuals segregated a disease-associated haplotype and were later shown to be mutation carriers. The
three individuals in generation I in FAM-1 (FAM-1/II-1, FAM-1/II-3, FAM-1/II-4) are obligate carriers. One unaffected
male in FAM-1 also displayed a linked haplotype. Age at diagnosis, if known, is in parentheses.
3/I-2 with metastasized cancer of unknown
primary site at age 61, and patient FAM-
3/II-4 with renal cell carcinoma at age 35.
2. HISTOPATHOLOGICAL FEATURES OF
TUMORS FROM HLRCC PATIENTS (I, II)
All seven renal cell carcinomas (from
patients FAM-1/III-7, FAM-1/III-9, FAM-
1/IV-4, FAM-1/IV-11, FAM-2/II-2, FAM-
2/II-3, FAM-3/II-4) were unilateral, solitary
lesions. The tumor diameter varied from 5 to
22 cm. Six of seven cases were metastasized
at the time of diagnosis, and only the patient
without metastases survived. Tumors mainly
displayed a papillary growth pattern, but
some of them also contained areas with
tubulo-papillary, solid, and cystic structures,
which are common to papillary tumors
(Reuter and Presti, 2000). The tumor cells
had a large amphophilic cytoplasm, large
nuclei, and inclusion-like eosinophilic
nucleoli. The Fuhrman nuclear grade was 3
to 4. Mitoses were moderate, and some
round cell infiltrates and apoptotic cell
groups were detected in all lesions. No
psammoma bodies or stromal macrophages
were present. Necroses and hemorrhages
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occurred in some tumors. The histological
picture of the carcinomas was unique; it was
distinct from papillary type 1 renal cell
carcinomas but had some resemblance to
type 2 carcinoma epithelium (Delahunt and
Eble, 1997). In immunohistochemical
stainings, all five tumors available for
analysis were negative for CK7 and four
tumors were positive for vimentin. Three
tumors were positive for EMA and HMFG2,
and two of these also for HMFG1. CK7 has
been considered to be a positive marker for
papillary tumors, yet further studies have
demonstrated that mainly papillary type 1
tumors express it (Delahunt and Eble, 1997).
Vimentin expression has been found to vary
in papillary carcinomas (Delahunt and Eble,
1997).
Nine skin lesions examined from
three patients (FAM-1/III-12, FAM-1/III-13,
FAM-3/III-5) were typical piloleiomyomas
with bundles of smooth muscle cells.
Smooth muscle origin was confirmed in two
tumors by positive immunohistochemistry
for desmin and _-SMA.
Uterine tumors from patients FAM-
1/III-12 and FAM-1/III-13 were typical
benign leiomyomas devoid of nuclear atypia,
increased mitotic index, or necrosis. One
uterine tumor from patient FAM-3/I-1 turned
out to be an atypical leiomyoma
characterized by cells with pleomorphic
nuclei. In the patient records and the Cancer
Registry, the tumor had been reported to be a
malignant uterine leiomyosarcoma. The
other tumor from the patient was a benign
leiomyoma.
Histology of the metastases from
lymph nodes, ovaries, and omentum from
the cancer of unknown origin (patient FAM-
1/III-5) was also re-examined. The
metastases displayed small epithelial cells
without clear organization but suggestive of
papillary pattern. Cells were well-defined
with a large cytoplasm, round and
sometimes multiple nuclei, and partly
eosinophilic enhanced nucleoli. However,
the origin of the primary tumor could not be
determined. The other two malignancies
available for analyses were a lobular
infiltrating carcinoma (from patient FAM-
1/III-13) and a III grade transitional cell
bladder carcinoma (from patient FAM-1/III-
10).
3. MOLECULAR FEATURES OF RENAL CELL
CARCINOMAS FROM HLRCC PATIENTS
(UNPUBLISHED DATA)
To evaluate the cytogenetic profile of seven
renal cell carcinomas from HLRCC families,
comparative genomic hybridization (CGH)
analysis was carried out. In CGH, the tumors
displayed a strikingly similar molecular
profile (Table 5). Of the seven tumors, five
harbored loss of genetic material in 4q21-
q33
Table 5. Alterations in HLRCC renal cell carcinomas in CGH.
Patient Alterations in tumor
FAM-1/III-7 - 4q, - 13q12-q31, + 16, + 17, and + 19
FAM-1/III-9 + 2q34-qter, - 3p14-q27, + 7, + 9q33-qter, + 17q23-qter, + 19p
FAM-1/IV-4 + 8, - 13q21-q31, - 14q12-q24, + 17, - 18, + 19, + 20q13-qter, - X
FAM-1/IV-11 - 4q, - 12pter-q22, - 13q13-q31, + 16, + 17q, - 18, + 19, + 20q, - X
FAM-2/II-2 - 4q, - 5q12-q34, + 9q32-qter, + 17
FAM-3/II-3 - 4q13-q33, - 9p, - 14q, + 16p, + 18p, - Xp11.2-p22.1
FAM-3/III-4 - 2p16-qter, - 4q21-qter, - 13q12-q31, + 17, - 18q, + 20, - X
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and four in 13q14-q27 and in Xp, and six
tumors displayed gains of genetic material in
17q23-qter.
4. LOCALIZATION OF THE HLRCC GENE
(I, II)
First, MET  and VHL  were excluded by
negative linkage (lod score < -2) at the
corresponding loci in renal cell carcinoma
patients from FAM-1. Then, a genome-wide
analysis was carried out in FAM-1. After
haplotype construction of chromosomal
regions displaying lod score 1 or higher,
only the telomeric end of the chromosome 1
long arm showed substantial positivity. To
confirm this, 12 microsatellite markers at
1q42-q44 were genotyped, which resulted in
the maximum lod score of 4.11 at marker
D1S2811. This was more than 10 times
higher than the level of significance for
simple inherited conditions (lod score 3).
Using the same set of markers, affected
individuals in FAM-2 and FAM-3 were
shown to share the 1q42-q44 region.
To further ensure the linkage to
1q42-q44, LOH analysis was performed on
the available tumors from affected
individuals. Loss of the wild-type allele in
tumor DNA compared with normal tissue
DNA was seen in 18 of 22 cases: 6 of 7
uterine leiomyomas, 7 of 7 cutaneous
leiomyomas, and 5 of 7 renal cell cancers.
The uterine leiomyosarcoma did not display
allele loss. When the LOH data on four renal
cell carcinomas and one uterine leiomyoma
from FAM-1 were incorporated into the
linkage data, the lod score at marker
D1S2811 was 5.31. These findings
supported the linkage to 1q42-q44 and
proposed that inactivating mutations in the
H L R C C  gene would cause the tumor
predisposition phenotype.
5. IDENTIFICATION OF THE DISEASE-
PREDISPOSING GENE FUMARATE
HYDRATASE (FUMARASE, FH) (III)
To reduce the target area from
approximately 14 cM defined by the
genome-wide searches (I) (Alam et al.,
2001), additional genotyping of individuals
from the Finnish families and the UK
families was performed.
In addition to markers from the
commercial sets, 28 novel short tandem
repeats were recognized and used for
genotyping. Critical recombinations were
identified in FAM-1 and UK family no. 307.
The disease gene was thus placed between
the clones BAC RPII-25B4 (centromeric
end), and RPII-553N16 (telomeric end)
comprising a region of 1.6 Mb. The minimal
region matched the data on deletions of 2.4
Mb and 1.9 Mb detected by FISH analysis in
the two UK families (nos 207 and 713),
respectively. By examination of allele loss in
tumors, the target region could not be
narrowed further.
In the target region, 6 known genes
and over 50 predicted genes or transcripts
were identified (Table 6).
Putative pathogenic sequence
changes were only detected in fumarate
hydratase (fumarase, FH). FH is located in
the BAC clones RP11-409K12 and RPII-
527D7. It encodes an enzyme component of
the mitochondrial tricarboxylic acid (Krebs)
cycle, thus playing a key role in cellular
energy metabolism. Mutations detected in
FH are depicted in Table 7. Mutations were
found in all three Finnish families and in 19
of 39 families from the UK. Sequence
changes included protein-truncating changes
(nonsense and frameshift mutations) (10/25),
large germline deletions (2/25), and
substitutions (12/25) or deletions (1/25) of
highly conserved amino acids. The missense
mutations were targeted at highly conserved
amino acids and were not reported as known
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polymorphisms. All the mutations
segregated with the disease phenotype and
none of them were detected in a panel of 150
control individuals. FAM-1 and FAM-2
shared the 2-bp deletion at nt 541, although
no common ancestry was known. In FAM-3,
a premature termination codon, Arg300X,
was detected. Six UK families carried the
same change Asn64Thr and three families
the nonsense mutation Arg58X.
Biallelic inactivation of FH was
observed in 21 of 22 HLRCC tumors; allelic
loss was detected in 18 of 22 tumors (see
section 4) and somatic mutations were
observed in three tumors. One renal cell
carcinoma displayed missense mutation
Met285Arg and the other carcinoma a 2-bp
deletion at codon 41 (Table 7). The uterine
leiomyosarcoma had acquired amino acid
change Glu319Asp (Table 7).
The data on germline mutations and
biallelic inactivation of FH in patients’
tumors suggested that absent or reduced
function of FH could be the cause of
tumorigenesis in HLRCC. To confirm this,
FH enzyme activity was measured in some
affected individuals. All patients with FH
germline mutation had decreased activity
compared with control individuals.
Consistent with these findings and with data
from the molecular genetic changes in
patients’ tumors, leiomyomas from affected
individuals had nearly undetectable enzyme
activity.
By RT-PCR, FH was shown to be
expressed at approximately similar levels in
a wide variety of human tissues.
6. ROLE OF FH IN TUMORIGENESIS OF
SPORADIC COUNTERPARTS OF TUMOR
TYPES OBSERVED IN HLRCC FAMILIES (IV,
UNPUBLISHED DATA)
Before identification of the disease-
predisposing gene, the role of the HLRCC
locus in development of sporadic tumors
was assessed by LOH analysis of tumor
Table 6. Candidate sequences identified in the target region.
Sequence type Protein function Number of
sequences identified
Known genes 6
RGS7 (regulator of G
protein signaling 7)
Modulates G protein-dependent signaling pathways
via GTPase-activating domain
FH (fumarate hydratase) Enzyme operating in the mitochondrial tricarboxylic
acid cycle
KMO (kynurenine 3-
monooxygenase)
Enzyme of the kynurenine pathway from tryptophan to
quinolinic acid
OPN3 (opsin 3) G-protein-coupled receptor
Similar to photoreceptors involved in
phototransduction
CHML (choroideremia-like) Supports geranylgeranylation of most Rab proteins
EXO1 (exonuclease 1) 5’ to 3’ exonuclease activity and Rnase H activity
Similar to the S. cerevisiae protein Exo1 which
interacts with Msh2 and is involved in mismatch repair
and recombination
ESTs
With homology 9
Without homology 32
Gene predictions
With homology 3
Without homology 14
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types associated with HLRCC. Analysis was
carried out on 10 cutaneous leiomyomas, 26
uter ine leiomyomas,  18 uter ine
leiomyosarcomas, and 58 renal cell
carcinomas (II, unpublished data). Allele
loss was detected in 1 of 24 informative
uterine leiomyomas, 5 of 17 informative
Table 7. FH mutations detected in Studies III and IV. Some of the mutations have been detected in
multiple families. Mutations reported to cause FH deficiency, which is a recessive disease characterized
by severe neurological impairment, are also included (see Discussion section 2.3).
Mutation Disease/origin Figure of FH1 Reference
Whole gene deletion MCL/HLRCC III
Whole gene deletion MCL/HLRCC III
Gln4X MCL/HLRCC III
Arg8Glu (s2) Sarcoma IV
58delC MCL/HLRCC III
66del74 FH deficiency Coughlin et al., 1998
121delTG (s) RCC3 (FAM-2) III
Arg58X MCL/HLRCC III
Arg58X MCL/HLRCC III
Arg58X MCL/HLRCC III
Asn64Thr MCL/HLRCC III
Asn64Thr MCL/HLRCC III
Asn64Thr MCL/HLRCC III
Asn64Thr MCL/HLRCC III
Asn64Thr MCL/HLRCC III
Asn64Thr MCL/HLRCC III
Ala74Pro MCL/HLRCC III
His137Arg MCL/HLRCC III
Gln142Arg MCL/HLRCC III
His153Arg LMS4 (uterus) IV
541delAG MCL/HLRCC III
541delAG MCL/HLRCC III
541delAG LM5 (skin) IV
Lys187Arg MCL/HLRCC III
Lys187Arg FH deficiency Coughlin et al., 1998
Lys187del MCL/HLRCC III
Arg190His MCL/HLRCC III
Arg190His FH deficiency Alam et al., unpublished data
Arg190Cys FH deficiency Rustin et al., 1997
IVS4-15T->G MCL/HLRCC III
Gly239Val MCL/HLRCC III
Leu240X (s) LMS (uterus) IV
Ala265Thr FH deficiency Coughlin et al., 1998
Phe269Cys FH deficiency Coughlin et al., 1998
Met285Arg (s) RCC (FAM-1) III
Arg300X MCL/HLRCC III
Arg300X (s) LM (skin) IV
Glu319Gln FH deficiency Bourgeron et al., 1994
Glu319Asp (s) LMS (uterus) (FAM-1) unpublished data
Asp383Val FH deficiency Coughlin et al., 1998
1220delG MCL/HLRCC III
1302insAAA FH deficiency Coughlin et al., 1998
Trp458X FH deficiency Coughlin et al., 1998
1 black vertical line depicts mutation site and white bar the truncated or absent protein product; 2 somatic mutation;
 rena renal cell carcinoma; 4 leiomyosarcoma; 5 leiomyoma
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uterine leiomyosarcomas, and 7 of 57
informative renal cell carcinomas. One renal
tumor displaying LOH was a papillary type
2 tumor.
Tumors analyzed for FH mutations
included 10 cutaneous leiomyomas, 41
uterine leiomyomas, 52 renal cell
carcinomas, 53 sarcomas, 29 prostate
carcinomas, and 15 lobular breast
carcinomas. Most of the tumors analyzed for
LOH were included in FH mutation
screening, but sequencing was not
performed on six papillary type 2 renal cell
carcinomas due to unsuccessful PCR. One of
these tumors had displayed LOH at the FH
locus.
Mutations were detected in one
uterine leiomyosarcoma, one cutaneous
leiomyoma, and one soft-tissue sarcoma.
The uterine leiomyosarcoma harbored
changes Leu240X and His153Arg. The
missense mutation His153Arg was present in
the patient’s germline and was not observed
in 134 control individuals. Compatible with
hereditary cancer susceptibility, the patient
was only 32 years old at the time of
leiomyosarcoma diagnosis.
Similarly, in addition to somatic
change Arg300X in the tumor, germline
mutation 541delAG was detected in the
patient with cutaneous leiomyoma. The
same 2-bp deletion had segregated in FAM-
1 and FAM-2, and therefore, the Finnish
population frequency of this putative
founder mutation was measured. The allele
was not present in 448 cancer-free controls.
Patient records revealed that the individual
had been operated on several times due to
skin leiomyomata but had no history of
malignancy.
Biallelic inactivation of FH was also
detected in the soft-tissue sarcoma, but in
this case, both events, missense mutation
Arg8Glu and loss of the wild-type FH allele,
occurred at the somatic level. Compatible
with tumor sequencing, the tumor had
displayed loss at the FH locus in previous
CGH analysis (Knuutila, pers. comm.). The
patient was 48 years old at the time of
diagnosis of metastasized soft-tissue
sarcoma in her right lower limb.
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DISCUSSION
1. HLRCC PHENOTYPE
1.1 Hereditary predisposition to uterine and
cutaneous leiomyomas, uterine
leiomyosarcoma, and renal cell carcinoma
The initial step of the study was recognition
of inherited susceptibility to renal cell
carcinoma and leiomyomas in a large
kindred (FAM-1). Compatible with
hereditary tumor predisposition, the family
included several individuals with multiple
tumors at an early age: four with renal cell
carcinoma, seventeen with leiomyomas of
the uterus and/or the skin, and two with
uterine leiomyosarcoma. The tumor
spectrum indicated a novel syndrome, as
inherited susceptibility to renal cell
carcinoma and uterine leiomyomas
(HLRCC) had not been previously
suggested. In our literature searches, we
were able to find one publication of two
leiomyomatosis kindreds from 1973 that
included a description of a 20-year-old
patient with uterine leiomyosarcoma and
metastasized renal cancer (Reed et al.,
1973). The patient and two of her four
siblings had leiomyomas of the skin, and the
mother had uterine leiomyomas. That the
phenotype of the patient highly resembled
the features in FAM-1 and that such a case
was found among the limited leimyomatosis
literature supported the notion of combined
predisposition to renal cancer and
leiomyomata.
The exceptional features of the renal
cell carcinomas in FAM-1 further confirmed
the hypothesis of a previously unrecognized
syndrome. The lesions were solitary and the
disease appeared aggressive, as all but one
patient had metastasized disease at the time
of diagnosis and died soon after between the
ages of 27 and 50 years. These features did
not correspond to the well-documented
familial renal cancer syndromes with VHL or
MET  germline mutations (Lamiell et al.,
1989; Zbar, 1995; Zbar and Lerman, 1998;
Walther et al., 1999; Iliopoulos and Eng,
2000). Furthermore, the renal tumors in
FAM-1 shared exceptional papillary
histology. The tumors displayed distinct
features with papillary growth pattern and
large cells containing abundant cytoplasm,
large nuclei with high nuclear grade
(Fuhrman grade 3-4), and prominent
nucleoli. The neoplastic epithelium did not
correspond to the histology in papillary
tumors with MET mutations, which display
features of type 1 papillary renal cell
carcinoma epithelium (Lubensky et al.,
1999), but had some resemblance to type 2
epithelium (Delahunt and Eble, 1997).
Moreover, that the unique histopathology
could be used as a tool to identify additional
families, spoke for a novel condition.
Adult renal tumors with similar
histology usually share distinct genetic
profiles (Störkel et al., 1997; Takahashi et
al., 2002). Compatible with these previous
observations, the tumors from FAM-1 and
the additional families displayed a similar
cytogenetic profile in CGH analysis. The
most common changes in the tumors
included losses of 13q, 4q, and Xp, and
gains of 17q. These alterations are found in
sporadic papillary renal cell carcinomas
(Jiang et al., 1998). However, gains of
chromosome 7, the most typical change in
papillary tumors with M E T  mutations
(Schmidt et al., 1997) and more often
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detected in papillary type 1 than type 2
tumors (Jiang et al., 1998), were not
common in the HLRCC carcinomas. Thus,
not only the histological but also the
molecular features of HLRCC tumors were
distinct.
The most conclusive evidence for
HLRCC being a novel syndrome was the
localization of the disease-predisposing gene
to 1q42-q43 by a genome-wide search.
Detection of wild-type allele loss in patients’
tumors, including renal cell carcinomas and
leiomyomas, further confirmed the linkage
and suggested that inactivation of the disease
gene would be the cause of HLRCC.
A hereditary syndrome predisposing
to multiple uterine and/or cutaneous
leiomyomas has previously been recognized
(multiple cutaneous and uterine
leiomyomatosis, MCL) and FAM-3 had in
fact originally been diagnosed with this
disease. However, over the course of the
study, the family turned out to include an
individual with early-onset renal cell
carcinoma. Histological features of the
lesion were similar to those seen in HLRCC
families FAM-1 and FAM-2, suggesting that
affected family members were also
predisposed to renal cell carcinoma.
Moreover, the molecular features in these
families were alike: FAM-3 was compatible
with linkage to the HLRCC locus and tumors
from FAM-3 harbored deletions targeted at
the wild-type chromosome. These findings
demonstrated that HLRCC and MCL are a
single disease with a variable phenotype.
This conclusion was further supported by a
subsequent and independent work reporting
linkage to the same locus in leiomyomatosis
families from the UK (Alam et al., 2001).
1.2 Penetrance and manifestations of
HLRCC
Leiomyomas of the skin and/or the uterus
were the predominant finding in the HLRCC
families. These tumors occurred in 87%
(26/30) of individuals with germline
mutation in the disease-predisposing gene,
which was identified as fumarate hydratase
(FH) (III) (see section 2). Penetrance of
leiomyomas was complete in FAM-1 and
FAM-3, but appeared to be 40% (2/5) in
FAM-2. Renal cell carcinoma occurred in
only 23% (7/30) of individuals [FAM-1 22%
(4/18), FAM-2 40% (2/5), FAM-3 14%
(1/7)] but at an early age, the age at
diagnosis varying from 26 to 48 years (mean
32 years). In addition, only 1 of the 39
leiomyomatosis families from the UK
appears to include an individual affected
with renal cell carcinoma (Tomlinson I.,
pers. comm.).
The interfamilial phenotypic
variability may be due to differences in the
first selection criterion used in family
identification. This explanation seems
reasonable because renal cancer appeared to
be rare in UK families, which were
identified based on the occurrence of
leiomyomata. Moreover, renal cancer was
not observed in families of the two patients
with germline mutations in F H, who had
been detected among apparently sporadic
cases of uterine leiomyosarcoma and
cutaneous leiomyomas (IV). Some of the
phenotypic variation could also be explained
by allelic heterogeneity in the FH gene. As
the germline mutations of only three
HLRCC families are currently known,
additional mutation data are required to shed
light on this issue. In addition to family
ascertainment and allelic heterogeneity,
either environmental or genetic modifiers
could play a role in clinical expression of
HLRCC, especially since intrafamilial
differences in the occurrence of renal cell
carcinoma and the number of leiomyomas
were observed.
Genetic modifiers have previously
been implicated in a few hereditary
syndromes. For example, germline APC
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mutations can predispose to hereditary colon
cancer syndromes with striking phenotypic
variation, such as FAP characterized by
development of hundreds or thousands of
colonic polyps and attenuated polyposis coli
by only a few polyps. In mice carrying a
mutant mouse Apc gene [Multiple Intestinal
neoplasia (Min) mice], a modifying locus
Mom-1 (Modifier of Min-1) was identified
(Dietrich et al., 1993). Mom-1 locus was
shown to control about 50% of genetic
variation in tumor number in the mice.
Another example is higher risk for ovarian
cancer in BRCA1 carriers with rare alleles of
HRAS-1  VNTR (Phelan et al., 1996).
Modifier effects in VHL have also been
proposed based on differences in the
presence and number of ocular tumors
within families (Webster et al., 1998).
Recently, an association between a certain
allele of cyclin D1  and risk of multiple
r e t i n a l  a n g i o m a s  a n d  C N S
hemagioblastomas in VHL patients was
observed (Zatyka et al., 2002). Complete
characterization of the natural history of
HLRCC and utilization of animal models in
investigation of environmental and genetic
modifiers will add to our knowledge of the
penetrance and variability of clinical
phenotype in HLRCC.
In addition to variability in clinical
expression, a tissue-specific cancer spectrum
is characteristic for hereditary cancer
syndromes. One explanation for this
puzzling observation could be alternative
functions of the gene product in different
tissues (Fearon, 1997). Although
determination of the HLRCC tumor
spectrum requires further study, the disease
apparently affects renal tissue and smooth
muscles of the uterus and the skin. The
kidney, uterus, and arrectores pilorum
muscle, the origin of cutaneous leiomyomas,
all develop from the mesoderm during
embryogenesis (Carlson, 1999). Thus, the
tissue manifestations in HLRCC could
reflect a common embryological origin of
proliferating cells in the different tumors.
Some resemblance to HLRCC phenotype
can be found in the animal model for
tuberous sclerosis (TS) (Ecker rat) and in the
Birt-Hogg-Dubé syndrome (BHD). The
Ecker rat harbors a germline mutation in the
rat Tsc2 gene and develops both renal cell
carcinoma and uterine leiomyomas (Yeung
et al., 1994; Everitt et al., 1995; Kobayashi
et al., 1995; Hino et al., 1999). The animals
are also predisposed to sarcomas of the
uterus and the spleen and pituitary tumors.
BHD is characterized by benign tumors of
the skin and is associated with renal
neoplasms, which display variable histology
including the papillary subtype (Toro et al.,
1999). Interestingly, the cutaneous tumors in
BHD arise in the hair follicle, which is
connected to the arrectores pilorum muscle.
It remains to be elucidated whether some
overlap exists between the pathways of
tumorigenesis in HLRCC, the animal model
for TS, and BHD that could explain the
similarities of tissue manifestations in these
diseases. Investigations on the putative
tissue-specific functions of FH, the protein
product of the disease gene, could also shed
light on the HLRCC phenotype.
2. FUMARATE HYDRATASE (FH) IN
TUMORIGENESIS
2.1 Mutations in FH cause tumor
development
Through identification of critical
recombinants in the disease families and
screening of known and predicted transcripts
at the HLRCC locus in 1q42-q43, the disease
gene, fumarate hydratase (fumarase, FH),
was identified. FH operates in the
mitochondrial tricarboxylic acid cycle
(Krebs cycle), playing a key role in cellular
energy metabolism. Germline mutations in
FH were detected in 25 of 42 families and
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included protein-truncating mutations
(10/25), large germline deletions (2/25), and
substitutions (12/25) or deletions (1/25) of
highly conserved amino acids. Both FH
alleles were inactivated in almost all
patients’ tumors through a germline
mutation in one allele and loss of or a
somatic mutation in the other allele (21 of 22
tumors from Finnish families). Thus, tumors
followed Knudson’s model of tumor
suppressor gene inactivation (Knudson,
1971). Furthermore, FH enzyme activity was
reduced in patients’ normal tissues and
nearly absent in their tumors. These findings
indicate that germline mutations in FH
predispose to HLRCC and that FH is likely
to be a tumor suppressor gene.
Further insights into the role of FH in
tumor development were gained by
analyzing sporadic tumors for FH mutations
and LOH at the FH locus. Studies included
sporadic forms of tumor types associated
with HLRCC. In the series of 194 tumors
studied for FH mutations, somatic mutations
appeared to be rare. Biallelic inactivation of
FH was detected in one uterine
leiomyosarcoma, one cutaneous leiomyoma
and one soft-tissue sarcoma. The two former
lesions originated from a germline mutation
and the sarcoma had acquired two somatic
hits. In the LOH analysis of 112 tumors, 13
tumors displayed allele loss, but none of the
tumors harbored FH mutations.
Several points can be raised from the
findings of the mutation and LOH analyses.
First, because two of the three cases with
somatic mutation also harbored an inherited
mutation, germline mutations in FH could
possibly be required for efficient
tumorigenesis. However, the finding of two
somatic hits in one lesion demonstrated that
FH could be involved in development of
nonhereditary tumors. Second, compatible
with the previous data (I, II, III, unpublished
data), biallelic inactivation of FH was
detected in all three tumors. The inactivation
model of FH seems remarkable in that two
hits can be found in nearly all tumors. Third,
that one uterine leiomyosarcoma arose from
a germline mutation further confirmed the
association of uterine leiomyosarcoma with
the HLRCC phenotype. Fourth, FH defects
were rare in the studied papillary type 2
renal cell carcinomas. Histologically, all
eleven tumors had some resemblance to
carcinomas from HLRCC families, but only
two lesions were highly similar to them. It is
conceivable that papillary type 2 renal cell
carcinomas may be divided into further
subgroups  wi th  d i s t ingu i shab le
histopathological and molecular features,
and thus, some other genes than FH might
also contribute to their development. Fifth,
none of the tumors displaying LOH harbored
FH mutations, which could be due to
random loss, haploinsufficiency, or some
alternative mechanism for gene inactivation.
Random loss would not be unlikely because
malignant tumors are known to harbor
numerous chromosomal abnormalities
(Fearon and Vogelstein, 1990; Devilee et al.,
2001). Haploinsufficiency has been
demonstrated with some other tumor
suppressor genes (Fero et al., 1998;
Venkatachalam et al., 1998; Cook and
McCaw, 2000; Quon and Berns, 2001).
Although the robust biallelic inactivation
pattern of F H in several hereditary and
sporadic tumors does not support this
phenomenon, haploinsufficiency could still
be involved in early development of some of
the lesions.
Not all cancer predisposition genes
are mutated in corresponding sporadic
lesions. The low somatic mutation rate in
BRCA1 and BRCA2 in sporadic breast and
ovarian carcinomas has been thought to
implicate the genes only being important for
tumorigenesis of familial cancer forms
(Takahashi et al., 1995; Lancaster et al.,
1996; Teng et al., 1996). BRCA1 has later
been demonstrated to be epigenetically
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inactivated in some sporadic tumors,
particularly those displaying LOH (Esteller
et al., 2000). Epigenetic silencing, especially
through promoter hyper-methylation, has
been discovered in most human tumor types,
and it is estimated to be involved in
inactivation of over 50% of tumor
suppressor genes in sporadic cancers (Jones
and Baylin, 2002). Investigation of the
alternative mechanisms of FH inactivation
will further enlighten the role of F H in
development of sporadic tumors.
2.2 Characteristics of FH
FH consists of 11 exons spanning over 20 kb
in 1q42-q43 and giving rise to a transcript of
1.5 kb (Craig et al., 1976; Despoisses et al.,
1984; Kinsella and Doonan, 1986). The
mature peptide is present both in the
mitochondria and the cytosol. The existence
of the two isoforms was first demonstrated
by detecting differences in the
electrophoretic mobility of the protein
(Tolley and Craig, 1975; Edwards and
Hopkinson, 1979a, 1979b). Studies on
human, pig, and rat fumarases have provided
evidence that the two isoforms are encoded
by a single gene (Tolley and Craig, 1975;
Edwards and Hopkinson, 1979a; Edwards
and Hopkinson, 1979b; Kobayashi and
Tuboi, 1983; O'Hare and Doonan, 1985).
Based on yeast studies, the proteins are
products of either two different transcripts
(Wu and Tzagoloff, 1987), a single
transcript with two translation initiation sites
(Tuboi et al., 1990; Suzuki et al., 1992), or a
single translation product distributed
between the cytosol and the mitochondrion
(Stein et al., 1994; Sass et al., 2001). Sass et
al. (2001) demonstrated the presence of only
one fumarase translation product, which is
targeted to mitochondria by an amino-
terminal signal peptide. The signal is then
removed by the mitochondrial processing
peptidase and some of the protein molecules
are transported back into the cytosol
resulting in identical mature cytosolic and
mitochondrial peptides. In humans, the
signal sequence for mitochondrial targeting
is thought to reside in the first exon
(GenBank U59309) (GenBank, 2002).
Crystal structures of bacterial
(FumC) and yeast (Fum1) fumarase proteins
have been characterized. Being a highly
conserved protein in evolution, human FH is
59% and 66% identical to the corresponding
proteins of E. coli and S. cerevisiae,
respectively. An even higher level of identity
resides within three specific regions: region
1 from His129 to Thr146 (amino acid
numbering is based on FumC sequence),
region 2 from Val182 to Glu200, and region
3 from Gly317 to Glu331 (Estevez et al.,
2002). A sequence motif in the third region
characterizes a superfamily of proteins
inc lud ing  fumarase ,  a spa r t a se ,
argininosuccinate lyase, adenylosuccinate
lyase, and crystallin. The enzymatically
active form of FH has been shown to operate
as a homotetramer (Hill and Teipel, 1971).
Each subunit has three domains, D1, D2 and
D3; the central domain, D2, consists of five
helixes forming a 20-helical core in the
tetramer (Weaver et al., 1995, 1998; Estevez
et al., 2002). The active site is composed of
side chains from three of the four subunits
(Weaver et al., 1995, 1997, 1998; Estevez et
al., 2002). Mutation Glu315Gln in E. coli
FumC, which is homologous to naturally
occurring human mutation Glu319Gln (see
Table 7), was shown to result in a 10-fold
reduction in the catalytic activity of the
protein (Estevez et al., 2002).
The well-known function of
mitochondrial homotetrameric FH is to
catalyze the conversion of fumarate to l-
malate in the tricarboxylic acid cycle
(TCAC) or Krebs cycle (Krebs and Johnson,
1937) (Figure 2). TCAC is the final common
route for the oxidation of fuel molecules -
amino acids, fatty acids, and carbohydrates.
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In this reaction series, free energy is released
via biological oxidations of two-carbon
molecules derived from primary substrates,
with concomitant reduction of coenzymes
NADH and FADH2. Reducing equivalents
are then fed into the mitochondrial electron
transport chain, and generation of high-
energy ATP molecules results (Stryer, 1995;
Rustin et al., 1997). For each two-carbon
compound entering TCAC, 10 molecules of
ATP are generated, 9 from the electron
transport chain and 1 directly in the cycle.
TCAC
Figure 2. The Krebs cycle.
Citrate synthase
Aconitase
Isocitrate
dehydrogenase
a-Ketoglutarate
dehydrogenase
Succinyl CoA
synthase
Succinate
dehydrogenase
Fumarase
Malate dehydrogenase
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functions only under aerobic conditions due
to a constant requirement of NAD+ and
FAD, which are produced when NADH and
FADH2 transfer their electrons to O2 in the
electron transport chain generating ATP.
The cycle integrates into several cellular
metabolic pathways by providing
intermediates for biosynthetic processes. For
example, FH is involved in the processing of
intermediates of the urea cycle (Medical
Biochemistry Page, 2002). However, the
role of the cytosolic isoform of FH is largely
unclear.
2.3 FH and other Krebs cycle enzymes in
human diseases
Fumarase deficiency, a progressive
mitochondrial encephalomyopathy, has been
previously described (Zinn et al., 1986). The
disease was shown to be a recessive disorder
caused by homozygous/ compound
heterozygous mutations in FH (Bourgeron et
al., 1993; Coughlin et al., 1993) (Table 7).
This syndrome is an example of the disease
group affecting the brain, skeletal muscle,
and other organs due to defects in
mitochondrial function (DiMauro et al.,
1985). Clinically, FH deficiency is
characterized by neurological impairment,
hypotonia, growth and developmental delay,
and fumaric aciduria (Whelan et al., 1983;
Zinn et al., 1986; Petrova-Benedict et al.,
1987; Gellera et al., 1990; Remes et al.,
1992; Bonioli et al., 1998; Kerrigan et al.,
2000; Manning et al., 2000). Neurological
features include retardation, seizures, and
visual impairment. Patients have
significantly reduced FH enzyme activity
(residual activity varies from 0.5% to 25%)
and usually die within a few months of birth
(Rustin et al., 1997), although some patients
have survived to their second decade
(Kerrigan et al., 2000). However, no tumors
have previously been reported in the patients
or their first-degree relatives. By careful
clinical and histopathological examination,
we were able to detect leiomyomas of the
skin in a mother of one FH deficiency
patient (III). Thus, these tumors, which may
be difficult to recognize, may have
previously gone unnoticed in these mutation
carriers. Interestingly, we found that the
nature and location of mutations differed
between FH deficiency and leiomyomatosis
patients (III). In the leiomyomatosis
families, mutations occurred significantly
more often in the 5’-end of the gene and
were more frequently truncating than
mutations in FH deficiency patients. One
simple explanation to these findings is that
truncating N-terminal changes might result
in embryonic death when homozygous and
thus be underrepresented in FH deficiency.
In addition, or alternatively, some mutations
causing FH deficiency might not be
penetrant for leiomyomatosis.
Defects in two other Krebs cycle
enzymes, _-ketoglutarate dehydrogenase
(oxoglutarate dehydrogenase, OGDH) and
succinate dehydrogenase (SDH), have also
been identified to cause mitochondrial
encephalomyopathy with neurological
defects and muscular involvement (Taylor et
al., 1996; Rustin et al., 1997; Rustin, 2002;
Rustin and Rotig, 2002). The molecular
genetic basis for _-ketoglutarate (_-KG)
deficiency has not been reported, but
homozygous mutations in SDHA have been
shown to underlie SDH deficiency
(Bourgeron et al., 1995; Parfait et al., 2000).
SDH has four subunits and operates in the
Krebs cycle and the electron transport chain
as a component of the mitochondrial
complex II. SDH includes the catalytic
domains flavoprotein SDHA and iron sulfur
protein SDHB, which are anchored to the
inner mitochondrial membrane by the other
two subunits SDHC, and SDHD.
Interestingly, mutations in subunits SDHD,
SDHC and SDHB have been identified to
cause hereditary predisposition to endocrine
Maija Kiuru
51
tumors in hereditary paraganglioma
syndrome (PGL) (Baysal et al., 2000;
Niemann and Muller, 2000; Astuti et al.,
2001b). In PGL, affected individuals
develop highly vascularized, benign, and
slow-growing tumors of the parasympathetic
ganglia referred to as paragangliomas. The
most common location for these lesions is
the carotid bifurcation. Mutations in SDHD
and SDHB have also been detected in
familial (Astuti et al., 2001a, 2001b) and
sporadic (Gimm et al., 2000; Astuti et al.,
2001b) pheochromocytoma. Typically,
hereditary pheochromocytoma is observed in
the context of VHL, MEN2, and NF1
syndromes (Marsh and Zori, 2002).
Pheochromocytoma is a catecholamine-
producing tumor occurring in sympathetic
gangl ions  of  the  body.  Most
pheochromocytomas arise in the adrenal
medulla, but approximately 10% of the
tumors are located in the abdominal and
mediastinal sympathetic ganglions and are
therefore sometimes called para-gangliomas.
2.4 Putative mechanisms of tumorigenesis in
HLRCC
At present, the mechanisms by which
mutations in FH lead to tumor development
remain obscure.  However,  some
explanations can be suggested based on the
findings of this study and the previous
literature.
First, FH could have unknown
functions unrelated to aerobic energy
production through the Krebs cycle. This
would not be surprising, especially
considering the poorly understood functions
of the cytosolic FH. Novel roles in cellular
processes have been demonstrated for other
enzymes of the Krebs cycle. The cytosolic
form of malate dehydrogenase was
discovered to be involved in the nucleotide
translocation pore (Hanss et al., 2002). Yeast
mitochondrial isocitrate dehydrogenase was
shown to bind to 5’ leader sequences of
mitochondrial mRNA and suggested to be
involved in translation regulation (de Jong et
al., 2000). In addition, yeast _-ketoglutarate
dehydrogenase was demonstrated to be a
bifunctional protein involved not only in the
Krebs cycle but also in stabilizing
mitochondrial DNA (Kaufman et al., 2000).
Second, a block in energy production
through the Krebs cycle could enhance
generation of reactive oxygen species (ROS)
and lead to an accelerated mutation rate by
affecting the balance of the electron
transport chain, as these two processes are
tightly coupled. ROS, which are primarily
produced at mitochondrial electron transport
chain complexes I and III (Liu et al., 2002),
have been implicated in carcinogenesis,
partially due to triggering generation of
mutations in nuclear and mitochondrial
DNA (Penta et al., 2001). Although the
exact role of mitochondrial DNA
rearrangements in tumorigenesis is obscure,
accumulation of mutations in the nuclear
DNA induced by ROS have been suggested
to drive tumor development and progression
(Jackson and Loeb, 2001). At present,
hypermutability of HLRCC-associated
tumors is not known. However, CGH, LOH,
and p53 mutation analyses on sporadic
leiomyomas, the most common tumor type
in HLRCC, suggest that these tumors appear
not to be unstable genetically (Jeffers et al.,
1995; Packenham et al., 1997; Mao et al.,
1999).
Third, a defect in cellular energy
production could induce growth-promoting
signals. Such signals could be metabolic
intermediates or ROS, which accumulate
due to the defective Krebs cycle and electron
transport chain in the mitochondria. This
could, for instance, trigger hypoxia response,
resulting in various downstream effects
promoting tumor growth. The role of
hypoxia in cell growth is widely documented
(Harris, 2002). Hypoxia response is known
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to lead to induced expression of genes
involved in an array of processes, such as
angiogenesis, glycolysis, growth factor
signaling, immortalization, genetic
instability, and tissue invasion and
metastasis.
Interestingly, hypoxia has been
proposed in the development of uterine
leiomyomas. Myometrial smooth muscle
cells proliferate in the luteal phase of the
menstrual cycle, and upon menstruation,
blood supply to the myometrium decreases
during myometrial contraction, possibly
inducing hypoxic state in the myometrial
smooth muscle cells. It has been
hypothesized that a subset of cells surviving
these repeated cycles of proliferation and
ischemia could acquire changes, giving them
an additional growth advantage and
rendering them putative progenitor cells of
leiomyomas (Fujii et al., 1999; Fukuhara et
al., 2002). Furthermore, early kidney
development occurs at an embryological
stage, when circulation is poorly developed
and oxygen levels are low (Carlson, 1999).
Thus, hypoxia could be speculated to
promote proliferation of a certain population
of cells in the uterus and kidney, leading to
organogenesis in embryonic development or
tumor formation in the adult.
A key transcription factor mediating
hypoxia response is HIF-1. HIF-1 is a
heterodimer that consists of the hypoxia
response factor HIF-1_ and the nuclear
translocator HIF-1ß. When oxygen levels are
low, the heterodimer binds to the hypoxia-
response elements activating transcription of
hypoxia-inducible genes. In the presence of
oxygen, HIF-1_ is ubiquitylated by VHL and
targeted to proteosomal degradation.
Interaction between HIF-1_ and VHL was
shown to require covalent modification of
HIF-1_ by prolyl hydroxylase (Bruick and
McKnight, 2001; Epstein et al., 2001; Ivan
et al., 2001; Jaakkola et al., 2001). Prolyl
hydroxylase is active in the presence of
oxygen, ferrous iron, and _-ketoglutarate (2-
oxoglutarate) (Ryle and Hausinger, 2002).
Interestingly, _-ketoglutarate is an
intermediate of the mitochondrial TCAC and
could be a candidate mediating oxygen
sensing. Involvement of mitochondria has
previously been proposed in activation of
hypoxia response via generation of ROS,
leading to accumulation of HIF-1_ (Chandel
et al., 2000). However, the role of
mitochondria in hypoxia response has not
been confirmed (Srinivas et al., 2001).
Activation of hypoxia response via
HIF-1_ is the most widely characterized
mechanism of tumorigenesis in the
hereditary renal cancer syndrome VHL.
Mutations in VHL prevent ubiquitylation of
HIF-1_, resulting in constant activation of
hypoxia-response genes. Hypoxia response
has also been proposed in SDH defects.
Paragangliomas, which develop in
individuals with mutations in SDH subunits,
occur most often in the carotid body. This
organ senses the body oxygen tension and
develops paraganglioma-like cellular
hyperplasia/anaplasia in individuals exposed
to chronic hypoxia (e.g. in people living at
high altitudes). At the molecular level,
hypoxia response has been demonstrated by
detecting elevated levels of expression of
angiogenic factors in hereditary and sporadic
paragangliomas (Jyung et al., 2000;
Gimenez-Roqueplo et al., 2001).
Loss of the SDHD locus has been
described in pheochromocytomas from VHL
patients, in addition to sporadic endocrine
tumors of different types (Kytölä et al.,
2001, 2002; Lui et al., 2002). Loss at 11q
appea red  to  be  spec i f i c  t o
pheochromocytomas from VHL patients, as
it was not detected in other lesions from the
patients (Lui et al., 2002). Although VHL-
associated pheochromo-cytomas did not
display mutations in SDHD, inactivation of
the gene could be involved in the
tumorigenetic pathway of these lesions.
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In conclusion, the tumorigenic
mechanisms of FH mutations require further
elucidation. Some overlap in clinical
manifestations and molecular background
appears to exist between the tumor
predisposition syndromes with mutations in
VHL, SDH, and FH genes. Understanding
the differences and similarities between
these diseases may shed light on how FH
mutations lead to tumor development in
HLRCC.
3. CLINICAL RELEVANCE AND
IMPLICATIONS FOR DIAGNOSIS, FOLLOW-
UP, AND TREATMENT OF HLRCC PATIENTS
The discovery of HLRCC and the
identification of F H as the disease-
predisposing gene provide the basis for
improved diagnosis, prevention, and
treatment of tumors in predisposed
individuals. Nevertheless, further work is
needed to clarify the natural history of
HLRCC. In particular, the HLRCC
incidence, tumor spectrum, and cancer risk
should be evaluated. The optimal methods
for prevention of malignancies should also
be assessed.
Due to variable manifestations and
clinical expression in HLRCC, identification
of HLRCC patients requires cooperation
between general practitioners and different
specialists, including dermatologists,
gynecologists,  urologists,  clinical
geneticists, and pathologists. Leiomyomas of
the skin could be valuable in identifying
individuals with hereditary cancer risk
because they are one of the most common
manifestations in these patients and are
detectable by gross inspection. The role of
cutaneous leiomyomas was emphasized by
detecting a F H germline mutation in one
patient with cutaneous leiomyomas out of
ten apparently sporadic cases (IV).
After identification of F H as the
causative gene for HLRCC, direct and
accurate diagnosis of affected individuals by
genetic testing has been possible. This
provides a means to guide individuals at risk
to preventive screenings and follow-up to
reduce cancer incidence and mortality.
Genetic testing has been provided to
HLRCC family members and has been
accompanied by information on the disease,
genetic counseling, and support. So far, we
have carried out genetic testing on 18
patients.
Although the HLRCC cancer risk has
not been accurately determined, a
predisposition to renal cancer and uterine
leiomyosarcoma clearly exists in a subset of
the leiomyomatosis families. Therefore,
regular screening for tumors in individuals at
risk to detect these tumors at an early stage
is reasonable. The screening methods in
HLRCC include abdominal and transvaginal
ultrasonography for detection of malignant
tumors of the kidney and the uterus,
respectively. Notably, without screening,
renal cell carcinoma in particular is often
diagnosed at a considerably more advanced
stage due to its nature of generating
symptoms relatively late (Motzer et al.,
1996). While the optimal frequency of
follow-up needs to be clarified, annual
examination, including abdominal and
transvaginal ultrasonography, can be
recommended because of the safety,
accuracy, and clinical applicability of these
screening methods (Mihara et al., 1999;
Dueholm et al., 2002). As regards uterine
manifestations, prophylactic hysterectomy
may be an option for an at-risk women
beyond child-bearing age.
Genetic testing and preventive
screening have a major psychosocial impact
on the patient. Thus, genetic counseling and
support should always be provided to these
patients. Patients should also be assisted in
making informed decisions and
understanding their disease risk and the
implications for cancer prevention. To
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benefit from the advances in molecular
characterization of HLRCC in the future,
collaborative efforts are needed to evaluate
the psychosocial influence and usefulness of
genetic testing and preventive screening in
HLRCC.
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CONCLUSIONS AND FUTURE PROSPECTS
This study describes a novel cancer
syndrome with predisposition to leiomyomas
of the uterus and the skin, uterine
leiomyosarcoma, and distinct papillary type
2 renal cell carcinoma (HLRCC). Tumor
predisposition in HLRCC is caused by
dominantly inherited mutation in fumarate
hydratase (fumarase, FH) in 1q42-q44. FH
is known to encode an enzyme component of
the mitochondrial tricarboxylic acid cycle.
FH is likely to be a tumor suppressor gene
based on the data on inactivating germline
mutations segregating in the disease
families, biallelic inactivation of F H in
patients’ tumors, reduced FH enzyme
activity in patients’ normal tissues, and
nearly undetectable activity in their tumors.
Mutational inactivation of F H
appeared to be rare in sporadic forms of
tumor types observed in HLRCC. Biallelic
inactivation of FH was detected in a uterine
leiomyosarcoma, a cutaneous leiomyoma,
and a soft-tissue sarcoma. Whereas the two
former tumors originated from a germline
mutation, the soft-tissue sarcoma displayed
two somatic hits, demonstrating the
involvement of FH in the development of
nonhereditary tumors. Not all cancer
predisposition genes are mutated in the
respective sporadic lesions but instead can
be inactivated through epigenetic
mechanisms. Further studies are needed to
reveal the role of alternative mechanisms in
FH inactivation in sporadic tumorigenesis.
Discovery of F H in cancer
predisposition clearly adds to our knowledge
of tumorigenesis. Notably, this study
provides the first evidence of a defect in a
Krebs cycle enzyme predisposing to
common human tumors. Challenging tasks
for the future include determining the role of
FH inactivation in sporadic tumors,
investigating the mechanisms by which FH
mutations lead to tumorigenesis,
characterizing the natural history of
HLRCC, and improving the diagnosis,
prevention, and treatment of the disease.
FH is the first gene shown to
predispose to uterine leiomyomas, one of the
predominant human tumor types. This
finding and future studies on genetic and
epigenetic inactivation of FH in sporadic
leiomyomas may provide clues to
understanding, preventing, and treating the
common forms of these lesions.
At present, the mechanisms by which
mutation in FH results in tumor
development remain speculative. For
example, FH could have unknown functions
unrelated to aerobic energy production.
Alternatively, a block in the Krebs cycle and
the electron transport chain could enhance
generation of ROS, thus accelerating the
mutation rate. It is also conceivable that a
defect in cellular energy production could
induce growth-promoting signals through,
for example, the hypoxia pathway. The
obscure mechanisms of tumorigenesis
caused by FH mutations open up a wide
field for future research.
Characterization of the natural
history of HLRCC is essential. This includes
determining HLRCC incidence, tumor
spectrum, cancer risk, and optimal methods
and intervals for screening of tumors. The
growing knowledge of the molecular
mechanisms involved could provide tools for
optimal diagnosis, prevention, and treatment
of hereditary and sporadic forms of the
disease.
Conclusions and future prospects
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